Podcast appearances and mentions of Thomas Fuchs

Irgendwas stimmt nicht. Ich sehe es, mein Kind hat Probleme, aber ich komme nicht ran. Übersehe ich etwas? Sehr viele Eltern umtreiben Sorgen, die manchmal ganz klein aber auch sehr groß sein können. Kiffen, Essstörungen, schlechte Noten, Probleme Freunde zu finden. Traurigkeit oder schon Depressionen, Aggressionen, Suchtverhalten, oder womöglich... gerät mein Kind auf die schiefe Bahn? Und dann die quälende Frage: Was habe ich falsch gemacht? Auch in liebevollen Familien laufen Dinge manchmal nicht gut. Die Scham ist oft groß, deswegen reden die meisten nicht darüber. Dabei hilft genau das. Dr. Thomas Fuchs ist Kinder- und Jugendpsychologe, seit 30 Jahren Therapeut und Autor des Buches „Was Kinder brauchen“. Er ist Vater von 3 Töchtern und hat neben all seiner Erfahrung als Therapeut einen sehr warmherzigen Blick auf Heranwachsende UND auf Eltern. Und den braucht es! Wir brauchen Verständnis für die Nöte unserer Kinder, auch wenn sie die in Trotz, Gleichgültigkeit oder Aggression hüllen. Wie kann es also gelingen, das Band wieder zu knüpfen und dem Kind auf dem Weg heraus zu helfen? Vielleicht helfen Euch Dinge, dies wir heute besprechen. Das würde mich sehr freuen. Schreibt mir, wie es Euch ergeht und was Euch unterstützt! Schreibt es mir gerne per Mail an hey@mwiemarlene.de oder kommentiert hier einfach unter der Folge oder auf Instagram. **Marlenes Instagram** https://www.instagram.com/marlenelufen/?hl=de **Der Instagram-Account von Thomas Fuchs** https://www.instagram.com/drthomasfuchs/ **Die Bücher von Thomas Fuchs** https://dr-thomas-fuchs.de/buecher/ **Das Bühnenprogramm von Thomas Fuchs** „9,5 Mio. entscheidende Minuten“ https://dr-thomas-fuchs.de/vortrage/ **Die Webseite von Thomas Fuchs** https://dr-thomas-fuchs.de

In dieser Folge spricht Evelyn mit Dr. Thomas Fuchs, seit 30 Jahren Psychotherapeut für Kinder und Jugendliche. Eine XXL-Folge mit vielen wertvollen Einblicken in Thomas Arbeit, aber vor allem ein leidenschaftlicher Appell an alle Erwachsenen Erziehung aus Kinder-Perspektive zu betrachten. Seelische Grundbedürfnisse zu priorisieren, klare Grenzen mit Herz und Empathie zu setzen, realistische Erwartungen zu haben, echtes Leben zuzumuten, bei Diagnosen wie z.B. ADHS Hilfe in Anspruch zu nehmen und Kinder in der digitalen Welt mit all ihren Chancen und Gefahren auf keinen Fall unbegleitet zu lassen – dafür setzt sich Thomas ein. Er wünscht sich „Let-it-be-Liste“ für Familien und stets ein gutes Gehör für die Stimmung der „Familiengitarre“. Das Leben mit Kindern ist anstrengend und Dinge können schiefgehen. Aber normalerweise geben Eltern ihr Bestes, sagt Thomas. Er ist davon überzeugt, dass sich jede Mühe lohnt. Schließlich dürfen unsere Kinder später einmal die Welt retten! Hier ist Dr. Thomas Fuchs auf Instagram zu finden: https://www.instagram.com/drthomasfuchs/ Du möchtest mehr über unsere Werbepartner erfahren? Hier findest du alle Infos & Rabatte: https://linktr.ee/AllemeineEltern Du möchtest Werbung in diesem Podcast schalten? Dann erfahre hier mehr über die Werbemöglichkeiten bei Seven.One Audio: https://www.seven.one/portfolio/sevenone-audio

Willkommen zur Silvesterschau des Datenschutz-Talk-Podcasts, direkt aus der Datenschutzzentrale der Migosens und den ehrwürdigen Hallen des Hauses der Wirtschaft in Mühlheim an der Ruhr. In dieser besonderen Folge blicken wir auf das Jahr 2024 zurück und haben spannende Gäste eingeladen: - Thomas Fuchs, hamburgischer Datenschutzbeauftragter - Simon Weidler, Manager EMEA Policy, Privacy and Data Regulation bei Meta - Dr. Paul Voigt, Partner und Head of TMT Germany bei Taylor Wessing Unsere Gastgeber, Laura Droschinski und Heiko Gossen, führen durch die Sendung und reflektieren über die wichtigsten Ereignisse und Entwicklungen im Datenschutz des vergangenen Jahres. Begleitet werden sie von den Migo-Tones, die musikalisch für Stimmung sorgen. In dieser Folge erwarten euch: - Ein Rückblick auf die Datenschutz-News und Themenfolgen des Jahres 2024 - Statistiken und Highlights aus dem Podcast-Jahr - Beliebte Outtakes und unterhaltsame Momente - Mit Thomas Fuchs sprechen wir u.a. über das 900.000 € Bußgeld seiner Behörde aus diesem Jahr, über sein Positionspapier zur Frage der personenbezogenen Daten in Large Language Models sowie über die Veränderung seiner Aufsichtspraxis zu seinem Vorgänger Prof. Dr. Johannes Caspar. - Simon Weidler äußert sich zu mehreren wichtigen Themen im Bereich Datenschutz. Er diskutiert die Datenschutzstrategien von Meta und wie das Unternehmen auf die sich ständig ändernden Datenschutzgesetze in Europa reagiert. Außerdem hebt er hervor, wie wichtig es ist, Datenschutz in die Unternehmenskultur zu integrieren und die Nutzer transparent über Datenverarbeitungspraktiken zu informieren. - Dr. Paul Voigt erklärt uns seine Sicht auf die zukünftige Relevanz der KI-Verordnung und wie sich die Datenschutzgesetzgebung in den USA unter dem neuen Präsidenten entwickeln könnte. Wir danken unseren diesjährigen Gästen und besonders unserem gesamten Team, das das ganze Jahr über hinter den Kulissen gearbeitet hat, um den Datenschutz-Talk-Podcast möglich zu machen. Ein besonderer Dank geht an Lara, Sarah, Tim, Dieter, David, Gregor, Natalia und Lothar. Schaltet ein und feiert mit uns das Ende eines ereignisreichen Jahres im Datenschutz! Weitere Infos, Blog und Newsletter finden Sie unter: https://migosens.de/newsroom/ Twitter: https://twitter.com/DS_Talk Übersicht aller Themenfolgen: https://migosens.de/datenschutz-podcast-themenfolgen/ (als eigener Feed: https://migosens.de/show/tf/feed/ddt/) Instagram: https://www.instagram.com/datenschutztalk_podcast/ Folge hier kommentieren: https://migosens.de/menschen-bilder-datenschutz-die-grosse-datenschutz-silvestershow-2024/ #TeamDatenschutz #TeamInfoSec #DSTalk #Jahresrückblick

Liebe, Angst, Empörung, Glück: Gefühle sind scheinbar zutiefst privat – stehen aber durchaus in Bezug zu Anderen und zu einem Außen. Und sie sind untrennbar vom Leib, sagt der Psychiater und Philosoph Thomas Fuchs. Mit Jürgen Wiebicke spricht er über das Wesen von Gefühlen. Von WDR 5.

„Jsem švorc,“ zní název jedné eseje od současného sociologa a filozofa Hartmuta Rosy. Autor si nestěžuje na to, že jeho práce málo nese, ale že on sám už nic dalšího nesnese. Nemá na mysli finanční, ale časovou insolvenci. Hartmut Rosa v eseji poznamenává: „Už nejsem schopen plnit své závazky. Naprosto selhávám. Kdyby měl tento příspěvek k něčemu být, potřeboval bych aspoň tři dny, ale já jej musím napsat za pár hodin.“ V tomto životním pocitu se patrně najde ledaskdo. Časovou tíseň navíc Rosa učinil svým výzkumným tématem: moderna je spjatá s tím, že jsme všichni, co se času týče, žebráci. Čím více se navíc snažíme přizpůsobit rychlosti, tím spíše se propadáme do zoufalství. Když se dnes nevyspíme a propracujeme noc, zítra budeme ještě citlivější na stres. Když se naučíme brát doplňky na zvyšování výkonnosti, můžeme ohrozit své zdraví; když se z toho navíc stane norma a ty doplňky bude brát stále více lidí, posune se to, co se od všech očekává. Teze o zrychlující se moderně není nepřesvědčivá. Ale staví na kontrastu vůči minulosti, která prý byla méně stresující. S tím je spjaté nebezpečí romantizace minulosti, v níž prý bylo na všechno více času. Ale copak to může být pravda? Vždyť pojem volného času je vyloženě moderní výdobytek. Život se navíc z jedné strany možná zrychluje, z druhé však zpomaluje. Vzrostl věk dožití a člověk na to zareagoval odkládáním rodičovství, manželství, dostudování. Mladí lidé získali čas na studium; „malý lidé“ čas na dětství. Třeba německý filozof Peter Sloterdijk proto na teorie zrychlování pohlíží skepticky. Nezavrhuje ji, ale vtahuje do hry ještě jedno hledisko. Co když to není tak, že objektivně stoupá stres, co když je to spíše tak, že se prohlubuje naše citlivost na stres? To není útok na citlivost. Sloterdijk nepochybuje o tom, že je spolutvůrkyní demokratických pořádků: i díky citlivosti jsme v druhém člověku rozpoznali druhé já a přisoudili každému rovná práva. Akorát se v nás také vytváří – působením té stejné citlivosti – nekonečný potenciál pro nespokojenost. „Všechny úlevy, které moderní společenství skýtají, jsou odsouzeny k tomu, aby byly pohlceny zvýšenou senzibilizací. Zákon rostoucí nespokojenosti v demokraciích stále čeká na své systematické zdůvodnění,“ poznamenává Peter Sloterdijk v knize Stres a svoboda. Kapitoly I. Vyrazit si s želvou na procházku [Začátek až 15:50] II. „Vyhlašuji časový bankrot.“ O časové insolvenci [15:50 až 42:30] III. Resonancí proti stresu? [42:30 až 58:40] IV. Jak stresující je přecitlivělost? [58:40 až konec] Bibliografie Walter Benjamin, „Das Paris des Second Empire bei Baudelaire“, in: Gesammelte Schriften, I, 2, Frankfurt am Main: Suhrkamp, 2012, str. 511–604. Thomas Fuchs, „O bezútěšnosti optimalizace a radosti z nesnází“, in: Bůh je mrtev. Nic není dovoleno, Praha: Echo Media, 2023, str. 282–292. Hartmut Rosa, „Demokracie potřebuje hlas, ale také uši a srdce“, in: Bůh je mrtev. Nic není dovoleno, Praha: Echo Media, 2023, str. 269–275. Hartmut Rosa, Unverfügbarkeit, Frankfurt am Main: Suhrkamp, 2020. Hartmut Rosa, When Monsters Roar and Angels Sing. Eine kleine Soziologie des Heavy Metal, Stuttgart: Kohlhammer, 2023. Peter Sloterdijk, Stress und Freiheit, Frankfurt am Main: Suhrkamp, 2011. „The worrying effects of working more and sleeping less“, in: BBC, 7. 7. 2017, https://www.bbc.com/worklife/article/20170707-the-worrying-effects-of-working-more-and-sleeping-less Shawn D. Youngstedt, Eric E. Goff et al., „Has Adult Sleep Duration Declined Over the Last 50+ Years?“, in: Sleep Med Rev., 28, 2016, str. 69–85, https://pmc.ncbi.nlm.nih.gov/articles/PMC4769964/ Celé epizody sledujte na www.forendors.cz/pravdaneexistujetm

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma e Biotech world.This week's commercialization news includes updates on Zepbound supply, Enjaymo's new home, and expanding access to HIV drugs. Medicare has tweaked rules for drug price talks, while GSK reports that its RSV vaccine protects against disease over three seasons. GSK's Viiv plans to expand the supply of HIV drugs in Africa, and Sanofi's rare disease drug finds a new home at Recordati. Other news includes a protein prediction winning the Chemistry Nobel and Alnylam submitting an important drug application. Trends suggest that biosimilars may make a mark in 2025, with incentives favoring them in the Medicare market. Protein prediction wins the Chemistry Nobel Prize, Alnylam submits a crucial drug application, Lilly partners with AI specialist Insitro to develop metabolic medicines, and Purespring raises $105 million for gene therapy for kidney disease. AI startup Basecamp allies with The Broad Institute to create 'programmable' genetic medicines. Additionally, Lilly appoints Mount Sinai scientist Thomas Fuchs as its first Chief AI Officer to lead AI initiatives in drug discovery and clinical trials. Other news includes J&J closing a cancer study, Alnylam seeking approval for a potential blockbuster drug, and Propharma receiving a regulatory and compliance award at CPhI.The Supreme Court declined to review a Texas abortion case related to emergency care, a blow to the Biden administration's efforts. A survey found that nearly 70% of healthcare organizations affected by cyberattacks experienced disruptions in patient care. Steward Health Care is auctioning off assets, including closing Norwood Hospital in Massachusetts. Baxter reported no structural damage at their North Carolina site affected by Hurricane Helene. The payer-provider relationship in healthcare is becoming more complex with consolidation and value-based care, leading to tensions over reimbursement and access.Kezar's lupus trial has been put on hold after four patient deaths, making it a potential buyout target. Investor Kevin Tang is interested in acquisition. Big pharma is also investing in cell and gene therapies, with companies like Lilly and Sanofi making moves in the industry. The Genscript Biotech Global Forum 2025 is coming up on January 15, offering a platform to discuss innovations and challenges in gene and cell therapy. Additionally, Lilly's obesity clinical program faces challenges, while Stealth's ultrarare disease candidate may not meet approval standards.Eli Lilly's obesity program is highlighted as a key factor in the company's dominance in the industry, with CEO David Ricks confident in their position. Wuxi Biologics faces uncertainty in the U.S. after setbacks, while big pharma companies show growing interest in cell and gene therapy. Five radiopharma biotechs are identified as potential buyout targets, and Trilink Biotechnologies introduces custom sets of mRNA for screening studies. Other news includes increased investment in cell and gene therapy, activist investor Starboard's stake in Pfizer, and Merck's success with Keytruda in head and neck cancer. AstraZeneca puts $2 billion towards heart disease drugs, Sanofi offloads a rare autoimmune drug, and AbbVie trims earnings guidance.

Die zyklische Zeit des Lebens und die lineare Zeit der Moderne. Dr. Dr. Thomas Fuchs ist Karl-Jaspers-Professor für Philosophische Grundlagen der Psychiatrie und Psychotherapie an der Ruprecht-Karls-Universität Heidelberg. Professor Fuchs hat Philosophie, Medizin und Wissenschaftstheorie studiert. Er ist in den Fächern Philosophie und auch Psychiatrie habilitiert. Seit 2005 ist Thomas Fuchs Professor für Psychiatrie und Psychotherapie an der Universität Heidelberg und seit 2010 Inhaber des Karl-Jaspers-Lehrstuhls für die philosophischen Grundlagen der Psychiatrie und Psychotherapie. 2023 erhielt Thomas Fuchs den Erich-Fromm-Preis für die Verteidigung humanistischen Denkens.

Meta hatte Mitte Juni 2024 angekündigt, seine KI (Künstliche Intelligenz) mit den Daten der Nutzerinnen und Nutzer von Facebook und Instagram zu trainieren. Wer das nicht wollte, musste widersprechen. Nach Intervention der Datenschutzaufsichtsbehörden verzichtet Meta in Europa vorerst auf das KI-Training. Wir haben Thomas Fuchs, den Hamburgischen Beauftragten für Datenschutz und Informationsfreiheit, dazu befragt.

Immer mehr Menschen klagen über Erschöpfung, Ängste und Depressionen – auch angesichts der krisenhaften Weltlage. Wie kann man seine Psyche besser schützen? Und wo muss sich die Gesellschaft verändern? Yves Bossart im Gespräch mit dem Psychiater und Philosophen Thomas Fuchs. Viele Menschen sind erschöpft, weil sie die natürlichen Kreisläufe des Lebens missachten, meint der Philosoph und Psychiater Thomas Fuchs. Sie sollten wieder lernen, die Rhythmen der Natur und des eigenen Körpers wahrzunehmen. Thomas Fuchs hat Medizin, Philosophie und Wissenschaftsgeschichte studiert und ist seit 2010 Karl-Jaspers-Professor für Philosophische Grundlagen der Psychiatrie und Psychotherapie in Heidelberg. Yves Bossart spricht mit ihm über die psychischen Belastungen der Gegenwart und darüber, was die Digitalisierung damit zu tun hat, warum junge Frauen besonders darunter leiden und was mögliche Auswege aus Erschöpfung und Entfremdung sein könnten. Wiederholung vom 7. Januar 2024

Immer mehr Menschen klagen über Erschöpfung, Ängste und Depressionen – auch angesichts der krisenhaften Weltlage. Wie kann man seine Psyche besser schützen? Und wo muss sich die Gesellschaft verändern? Yves Bossart im Gespräch mit dem Psychiater und Philosophen Thomas Fuchs. Viele Menschen sind erschöpft, weil sie die natürlichen Kreisläufe des Lebens missachten, meint der Philosoph und Psychiater Thomas Fuchs. Sie sollten wieder lernen, die Rhythmen der Natur und des eigenen Körpers wahrzunehmen. Thomas Fuchs hat Medizin, Philosophie und Wissenschaftsgeschichte studiert und ist seit 2010 Karl-Jaspers-Professor für Philosophische Grundlagen der Psychiatrie und Psychotherapie in Heidelberg. Yves Bossart spricht mit ihm über die psychischen Belastungen der Gegenwart und darüber, was die Digitalisierung damit zu tun hat, warum junge Frauen besonders darunter leiden und was mögliche Auswege aus Erschöpfung und Entfremdung sein könnten. Wiederholung vom 7. Januar 2024

Improved cancer diagnostics — and improved patient outcomes — could be among the changes generative AI will bring to the healthcare industry, thanks to Paige, the first company with an FDA-approved tool for cancer diagnosis. In this episode of NVIDIA's AI Podcast, host Noah Kravitz speaks with Paige cofounder and Chief Scientific Officer Thomas Fuchs. He's also dean of artificial intelligence and human health at the Icahn School of Medicine at Mount Sinai. Tune in to hear Fuchs on machine learning and AI applications and how technology brings better precision and care to the medical industry.

+++ Hier findet ihr alle Infos zu unseren Sponsoren, Links zu den Rabattaktionen etc.: lnkfi.re/einfachganzleben +++»Willkommen, Tag! Ich erwähle dich mit allem, was du bringst.« Mit diesen Worten begrüßt Jens Corssen, renommierter Psychologe und Experte für Persönlichkeitsentwicklung, an jedem Morgen den neuen Tag und bejaht so das Leben mit all seinen Facetten. Im Gespräch mit Jutta Ribbrock stellt er die von ihm entwickelte Philosophie und Praxis des Selbst-Entwicklers vor, die auch Grundlage seines Coachings von Manager:innen und Spitzensportler:innen ist. Er gibt konkrete Tipps, wie wir zu mehr Zufriedenheit und Erfolg finden. Und er verrät das Geheimnis seiner langen Ehe.Zum Weiterhören und Stöbern:selbstentwickler.comJens Corssen & Christiane Tramitz, Ich und die anderen – Als Selbst-Entwickler zu gelingenden Beziehungen (Buch und Hörbuch)Jens Corssen, Stefan Gröner & Stephanie Ehrenschwendner, Der Team-Entwickler – Gemeinsam gewinnen lernen (Buch und Hörbuch)Jens Corssen & Thomas Fuchs, Familienglück – Wie wir durch Anerkennung eine erfüllte Eltern-Kind-Beziehung erreichen (Buch und Hörbuch)Jens Corssen über Lieben als Haltung und das Geheimnis seiner langen Ehe (im Podcast-Gespräch mit Jutta Ribbrock)Die Titelmelodie dieses Podcasts findet ihr auf dem Album balance moods – Ein Tag in der Natur.Noch viel mehr Tipps zu einem bewussten Lebensstil findet ihr auf einfachganzleben.de.Besucht uns auch bei Facebook und Instagram.Weitere Podcasts von argon podcast gibt es unter argon-podcast.de.Ihr habt Fragen, Lob, Kritik oder Anmerkungen? Dann meldet euch auch gern per Mail: einfachganzleben@argon-verlag.deIhr könnt Jutta auch direkt schreiben: jutta@juttaribbrock.deUnd ihr findet sie bei Instagram: @jutta_ribbrock Hosted on Acast. See acast.com/privacy for more information.

In Episode 123 thematisieren Timo und Michael ein gesellschaftlich sehr relevantes Thema: die erschöpfte Gesellschaft. Auslöser für diese Episode ist dabei ein Interview im SRF mit Dr. Prof. Thomas Fuchs das die beiden Podcast-Hosts sichtlich inspiriert hat. Die Erschöpfung oder Ermüdung der Gesellschaft hat viele Hintergründe, die ausführlich thematisiert werden. Außerdem geht es um den Einfluss virtueller Welten, Berührungen und mögliche Maßnahmen als Gesellschaft oder Individuum damit umzugehen.

Derek and Thomas Fuchs are talking Twins both on and off the field with Seth Stohs from Twins Daily, also look ahead to the Timberwolves vs. Nuggets series. See omnystudio.com/listener for privacy information.

Derek Hanson, along with producers Thomas Fuchs and Reggie Funk talk all things NCAA basketball (both men and women), Twins baseball, interleague games this early, and Jeff Kolpack, host of the "Golf Show" on 740 the Fan (10am Saturday mornings) previews his interview with PGA Pro Tom Hoge. See omnystudio.com/listener for privacy information.

Die wirksamste Form von Begegnung braucht die Bereitschaft, sich zu öffnen und aufeinander einzulassen. Passend zum Jahresthema BEGEGNUNG spreche ich mit Prof. Dr. Thomas Fuchs über die vielfältigen Formen, wie unsere Körper in Resonanz kommen. Der promovierte Philosoph lehrt, forscht und arbeitet an der Uni Heidelberg. Sein Faible gilt der Leib-Phänomenologie: Unser Körper (oder: Leib) ist die Grundlage für alles Kognitive und somit die Grundlage für jede Begegnung, jedes Miteinander, jedes Agieren. Dabei sind wir auf den Kontakt mit anderen angewiesen – wie können wir einander berühren, Resonanz-Räume schaffen und in einer Welt wachsender virtueller Kontakte wahrhaftige Berührung gestalten? Danke für dieses berührende Gespräch! Thomas Fuchs Gedanken (in min): 01:20 Das Phänomen des Leibes 04:30 Resonanz und Berührung 10:45 Leib und Seele berühren 18:58 Gegenwärtig sein 24:45 Resonanz und Interaktion 30:01 Wahrnehmung bei Events sinnvoll einsetzen 41:01 Digitale Kontakte vs. Reale Begegnung 50:09 Leibliche Präsenz kultivieren Prof. Dr. Thomas Fuchs: https://bit.ly/DrDrThomasFuchs Podcast zu Phänomenologie des Hasses: https://bit.ly/PodcastPhaenomenologiedesHasses Publikation zu Empathie und Virtualität: https://bit.ly/EmpathieundVirtualität Hartmut Rosa, Resonanz: https://bit.ly/GrenzenlosesEventDesign Begegnet mir! LinkedIn: https://bit.ly/3olKIHK Newsletter: https://bit.ly/ablaufregisseur Mein Buch: https://bit.ly/begegnunggestalten Chris Cuhls ist als Regisseur, Konzepter und Berater mit diesem Podcast auf der Suche nach den Prinzipien der Wirkung – für Momente, die haften bleiben und Erlebnisse, die Wandel bewirken.

Derek Hanson and Jack Michaels with the Tuesday "Twins Wrap" previewing the upcoming 2024 season with Twins broadcasting legend Dick Bremer.  Also, Thomas Fuchs and Derek talk about the new kickoff rules that will be coming in 2024 to the NFL. See omnystudio.com/listener for privacy information.

Derek's birthday show with Thomas Fuchs producing and John Holler, Vikings beat writer for the USA Today joins the show to celebrate!See omnystudio.com/listener for privacy information.

Derek Hanson, Thomas Fuchs and Kevin Kennedy analyze Anthony Edwards' dunk everyone is talking about, breakdown ESPN's deal with the College Football Playoff for almost $8billion and Twins Broadcasting Legend Dick Bremer and Jack Michaels join for the Tuesday "Twins Wrap" to preview the upcoming 2024 season.See omnystudio.com/listener for privacy information.

Derek Hanson, Thomas Fuchs and Kevin Kennedy talk about the three Twins pitchers who are injured, the Vikings getting another first round draft pick after their trade with the Texans and the Packers releasing Aaron Jones and Minnesota snapping him up right away. See omnystudio.com/listener for privacy information.

Dr. Thomas Fuchs, Dean of AI, Mount Sinai, and founder, Paige.AI, and Peggy Smedley talk about the premise of his work and understanding the processes of ML (machine learning) and how it impacts healthcare such as cancer research. He says Mount Sinai currently uses AI (artificial intelligence) across the board.   They also discuss:          Surprising insights he has discovered being in this field of work.          How AI and ML can help patients—and concerns that many people have surrounding AI and ML.          The partnership between Paige.AI and Microsoft and how it is involved in the foundation models. Tags: IoT, Internet of Things, Peggy Smedley, artificial intelligence, machine learning, big data, digital transformation, 5G cloud, sustainability, future of work, podcast Dr. Thomas Fuchs, Mount Sinai, Paige.AI

Dr. Thomas Fuchs, Dean of AI, Mount Sinai, and founder, Paige.AI, and Peggy Smedley talk about the premise of his work and understanding the processes of ML (machine learning) and how it impacts healthcare such as cancer research. He says Mount Sinai currently uses AI (artificial intelligence) across the board.   They also discuss:          Surprising insights he has discovered being in this field of work.          How AI and ML can help patients—and concerns that many people have surrounding AI and ML.          The partnership between Paige.AI and Microsoft and how it is involved in the foundation models. Tags: IoT, Internet of Things, Peggy Smedley, artificial intelligence, machine learning, big data, digital transformation, 5G cloud, sustainability, future of work, podcast Dr. Thomas Fuchs, Mount Sinai, Paige.AI

Thomas Fuchs

Immer mehr Menschen klagen über Erschöpfung, Ängste und Depressionen – auch angesichts der krisenhaften Weltlage. Wie kann man seine Psyche besser schützen? Und wo muss sich die Gesellschaft verändern? Yves Bossart im Gespräch mit dem Psychiater und Philosophen Thomas Fuchs. Viele Menschen sind erschöpft, weil sie die natürlichen Kreisläufe des Lebens missachten, meint der Philosoph und Psychiater Thomas Fuchs. Sie sollten wieder lernen, die Rhythmen der Natur und des eigenen Körpers wahrzunehmen. Thomas Fuchs hat Medizin, Philosophie und Wissenschaftsgeschichte studiert und ist seit 2010 Karl-Jaspers-Professor für Philosophische Grundlagen der Psychiatrie und Psychotherapie in Heidelberg. Yves Bossart spricht mit ihm über die psychischen Belastungen der Gegenwart und darüber, was die Digitalisierung damit zu tun hat, warum junge Frauen besonders darunter leiden und was mögliche Auswege aus Erschöpfung und Entfremdung sein könnten.

Immer mehr Menschen klagen über Erschöpfung, Ängste und Depressionen – auch angesichts der krisenhaften Weltlage. Wie kann man seine Psyche besser schützen? Und wo muss sich die Gesellschaft verändern? Yves Bossart im Gespräch mit dem Psychiater und Philosophen Thomas Fuchs. Viele Menschen sind erschöpft, weil sie die natürlichen Kreisläufe des Lebens missachten, meint der Philosoph und Psychiater Thomas Fuchs. Sie sollten wieder lernen, die Rhythmen der Natur und des eigenen Körpers wahrzunehmen. Thomas Fuchs hat Medizin, Philosophie und Wissenschaftsgeschichte studiert und ist seit 2010 Karl-Jaspers-Professor für Philosophische Grundlagen der Psychiatrie und Psychotherapie in Heidelberg. Yves Bossart spricht mit ihm über die psychischen Belastungen der Gegenwart und darüber, was die Digitalisierung damit zu tun hat, warum junge Frauen besonders darunter leiden und was mögliche Auswege aus Erschöpfung und Entfremdung sein könnten.

show site: https://thinkfuture.com breaking news in AI: https://aidaily.us telegram channel: https://t.me/thinkfutureumthomas' linkedin: https://www.linkedin.com/in/fuchsthomas/page ai: https://paige.ai --- Chris and Thomas Fuchs dive deep into the world of AI-driven healthcare. In this episode, they explore how Paige Pathology harnesses the power of artificial intelligence to revolutionize the diagnosis and treatment of cancer. Thomas shares impressive statistics from Paige Pathology's AI system, which has notably reduced diagnostic error rates by 70% without increasing false positives. This breakthrough demonstrates AI's remarkable potential to enhance patient care and accuracy in medical diagnostics. The conversation then shifts to the broader impact of AI in healthcare, especially in cancer treatment. Thomas and Chris discuss how AI can democratize healthcare access, improve patient outcomes, and offer advanced imaging and analysis for more precise treatments. A key topic of discussion revolves around the detection and treatment of rare cancers. They emphasize the importance of identifying specific mutations for targeted drug therapy and the benefits of early detection through innovative methods like liquid biopsies. Despite these advancements, Thomas and Chris acknowledge the current limitations of AI in healthcare. They agree that while AI can significantly assist pathologists, it cannot yet independently make complete diagnoses. However, they are optimistic about AI's future role in automating screening tasks and providing a comprehensive view of patient health. The episode concludes with a focus on the crucial development of AI in medicine, emphasizing its potential to fill existing gaps in healthcare, increase efficiency, and, most importantly, save lives. This episode is a must-listen for anyone interested in the intersection of technology and healthcare, and the ways AI is shaping the future of medicine. --- Send in a voice message: https://podcasters.spotify.com/pod/show/thinkfuture/message Support this podcast: https://podcasters.spotify.com/pod/show/thinkfuture/support

"Mark Twain und Ernest Hemingway in Deutschland " von Thomas Fuchs - Rezension von Manfred Orlick - Literaturkritik.de Hördauer (ca. 8 Minuten) Es ist schon bemerkenswert, dass Deutschland im 19. und 20. Jahrhundert bei amerikanischen Schriftstellern ein beliebtes Reiseziel war. Die Beweggründe waren sehr unterschiedlich – von Neugier über neue Eindrücke bis hin zum Rückzug aus dem stressigen Schriftstellerleben. Zahlreiche Reiseeindrücke fanden dann ihren Niederschlag in ihren Werken. …“ Eine Rezension von Manfred Orlick Den Text der Rezension finden Sie hier. Sprecher, Schnitt und Realisation: Uwe Kullnick --- Send in a voice message: https://podcasters.spotify.com/pod/show/hoerbahn/message

Bald kann man Facebook und Instagram gegen Bezahlung werbefrei nutzen. Im Grundsatz sei das gut, sagt Thomas Fuchs, Hamburgischer Beauftragter für Datenschutz. Die entscheidende Frage sei aber, ob der Preis dafür stimme. Viele werde dieser abschrecken. Von WDR 5.

Why scientists are trying to make anemones act like corals, and why it's so hard to make pharmaceuticals for brain diseases   First up on this week's show, coaxing anemones to make rocks. Newsletter Editor Christie Wilcox joins host Sarah Crespi to discuss the difficulties of raising coral in the lab and a research group that's instead trying to pin down the process of biomineralization by inserting coral genes into easy-to-maintain anemones.   Next on the show, a look at why therapeutics for both neurodegenerative disease and psychiatric illness are lagging behind other kinds of medicines. Steve Hyman, director of the Stanley Center for Psychiatric Research at the Broad Institute, talks with Sarah about some of the stumbling blocks to developing drugs for the brain—including a lack of diverse genome sequences—and what researchers are doing to get things back on track.   Finally, in a sponsored segment from the Science/AAAS Custom Publishing Office, associate editor Jackie Oberst discusses with Thomas Fuchs, dean of artificial intelligence (AI) and human health and professor of computational pathology and computer science at the Icahn School of Medicine at Mount Sinai, the potential and evolving role of AI in health care. This segment is sponsored by the Icahn School of Medicine at Mount Sinai.   This week's episode was produced with help from Podigy.   About the Science Podcast   Authors: Christie Wilcox; Sarah Crespi   Episode page: https://www.science.org/doi/10.1126/science.adm6756

Why scientists are trying to make anemones act like corals, and why it's so hard to make pharmaceuticals for brain diseases   First up on this week's show, coaxing anemones to make rocks. Newsletter Editor Christie Wilcox joins host Sarah Crespi to discuss the difficulties of raising coral in the lab and a research group that's instead trying to pin down the process of biomineralization by inserting coral genes into easy-to-maintain anemones.   Next on the show, a look at why therapeutics for both neurodegenerative disease and psychiatric illness are lagging behind other kinds of medicines. Steve Hyman, director of the Stanley Center for Psychiatric Research at the Broad Institute, talks with Sarah about some of the stumbling blocks to developing drugs for the brain—including a lack of diverse genome sequences—and what researchers are doing to get things back on track.   Finally, in a sponsored segment from the Science/AAAS Custom Publishing Office, associate editor Jackie Oberst discusses with Thomas Fuchs, dean of artificial intelligence (AI) and human health and professor of computational pathology and computer science at the Icahn School of Medicine at Mount Sinai, the potential and evolving role of AI in health care. This segment is sponsored by the Icahn School of Medicine at Mount Sinai.   This week's episode was produced with help from Podigy.   About the Science Podcast   Authors: Christie Wilcox; Sarah Crespi   Episode page: https://www.science.org/doi/10.1126/science.adm6756

Dr Thomas Fuchs (@fuchsthomas) is the cofounder and chief scientist at Paige, which is is a pioneer in the groundbreaking field of computational pathology and cancer diagnosis.   We discuss the process of diagnosing cancer, some of the processes that technology can help with and how AI is transforming cancer diagnosis forever.   You can find out more about Paige at https://www.paige.ai/   Fill out the quick form here: https://forms.gle/AH1tusHRXkC3N5yM6 and be in with the chance of winning an Amazon Gift card   Get your 2-month free trial of my Inner Circle here https://bit.ly/InnerCircle2MTrial   Join the FREE Facebook group for The Michael Brian Show at https://www.facebook.com/groups/themichaelbrianshow   Follow Mike on Facebook Instagram & Twitter

Derek Hanson and Thomas Fuchs talk all things NFC North after week one of the NFL season.See omnystudio.com/listener for privacy information.

New podcast episode season six episode 131. Jason Stoughton is joined by Dr. Thomas Fuchs, Department Chair of Artificial Intelligence and Human Health at Mt. Sinai and Founder of Paige, to talk about AI in medicine and healthcare and the amazing things Paige is doing to empower pathologists and transform oncology. AI holds the promise of transforming healthcare across the entire ecosystem. Thomas and Jason talk about the challenges and opportunities today and what the industry might look like in the near future. After years of slow going things are moving fast. Sign up for The Pulse of AI newsletter at www.thepulseofai.com and follow Jason on X (formerly twitter) @thepulseofai  

Niko Härting spricht mit Thomas Fuchs, seit November 2021 Hamburgischer Landesbeauftragter für Datenschutz und Informationsfreiheit. Seit den 90er-Jahren war Thomas Fuchs in der Hamburgischen Kulturverwaltung tätig und befasste sich unter anderem mit der Planung der Elbphilharmonie. Von 2008 bis 2021 war er Direktor der Medienanstalt Hamburg/Schleswig-Holstein und war dort zuletzt auch für Intermediäre wie Google zuständig. In der Corona-Krise ging seine Behörde gegen Google vor, als man bei Google begann, Seiten des Bundesgesundheitsministeriums in den Suchergebnissen zu Corona hervorzuheben. Die Zusammenarbeit von Google und dem Gesundheitsministerium wurde von vielen begrüßt, um Desinformation zu bekämpfen. Nichtsdestotrotz handelte es sich um eine Bevorzugung staatlicher Informationen durch ein marktmächtiges Unternehmen, über deren Rechtmäßigkeit das Verwaltungsgericht Schleswig in geraumer Zeit entscheiden wird. Thomas Fuchs ist überzeugt, dass Gesetze zur Datennutzung wie das geplante Gesundheitsdatennutzungsgesetz oder der europäische Data Act das Datenschutzrecht nicht „unberührt“ lassen können. Wenn eine massenhafte Nutzung von Daten gesellschaftlich gewollt ist, sei es nicht realistisch, einwilligungsbasiert vorzugehen. Fuchs kritisiert eine „falsche Zentrierung“ auf die Einwilligung und ist der Überzeugung, dass man in Zukunft verstärkt auf „Opt-Out-Systeme“ setzen wird. Datenschutzbehörden dürften bei dieser Entwicklung keine „Bremsklötze“ sein, sondern sollten hieran gestaltend mitwirken. Der Gesetzgeber sei gefordert, den „Paradigmenwechsel“ von der Einwilligung zu „Opt-Out-Systemen“ gesetzlich auszugestalten. Dass die DSGVO in zahlreichen Rechtsakten als „unberührt“ bezeichnet wird, kann und darf nicht das letzte Wort des Gesetzgebers sein. Bei seinem Amtsantritt als oberster Datenschützer des Stadtstaates Hamburg war Thomas Fuchs beeindruckt von dem Sachverstand und der Kompetenz der Mitarbeiterinnen und Mitarbeiter seiner Behörde. Für problematisch erachtet es Fuchs jedoch, dass die Arbeit der Behörde ganz überwiegend „beschwerdegetrieben“ ist und kaum dazu kommt, eigene Schwerpunkte zu setzen. Thomas Fuchs hat sich eine Optimierung der Prozesse zur Bearbeitung von Beschwerden vorgenommen durch Digitalisierung und durch eine effizientere Nutzung der personellen Ressourcen der Behörde. Gelungen ist dadurch eine proaktive Untersuchung der Datenschutzkonformität von Abläufen bei Maklerbüros in Hamburg. Informationsfreiheit und Transparenz werden in Hamburg groß geschrieben. Thomas Fuchs berichtet über das Transparenzregister, das es in Hamburg bereits seit einigen Jahren gibt. Für „normale Verwaltungsvorgänge“ gilt weiter Informationsfreiheit mit einer Abhilfequote der Hamburgischen Behörde, die laut Fuchs bei 90 % liegt. Thomas Fuchs spricht über die geplanten Reformen bei der Datenschutzkonferenz („DSK 2.0.“) und bricht am Schluss eine Lanze für den Datenschutz im öffentlichen Bereich. Das Datenschutzrecht ist nach Fuchs‘ Überzeugung zu sehr Wirtschaftsrecht geworden. Die behördliche Datennutzung müsse jedoch auch weiterhin stark im Fokus der Datenschutzaufsicht liegen. Der Schutz des Bürgers gegen staatliche Übergriffe hält Fuchs für eine selbstverständliche Kernaufgabe seiner Behörde.

“Die Art und Weise, wie Medizin heute betrieben wird, wird uns in 20-30 Jahren mittelalterlich erscheinen.”Prof. Thomas Fuchs ist KI-Forscher am renommierten Mount-Sinai-Krankenhaus in New York. Als Co-Founder des Pathologie-Start-ups “Paige” und Co-Direktor des Hasso-Plattner-Instituts für Digital Health / Mount Sinai beschäftigt er sich mit philanthrophischen KI-Anwendungen, insbesondere im Bereich der medizinischen Bildgebung.Show-Notes:00:00 Einführung11:49 Vision: KI im Gesundheitswesen25:38 Leben ohne Krankheiten?28:53 ChatGPT: Auswirkungen auf die Medizin35:55 Alles Open Source?49:36 Das nächste Große Ding im Gesundheitswesen52:30 Selbst Gründen? Was bitte?59:37 Technologische Singularität

As AI continues to develop, scientists are figuring out new and improved ways to use it in the medical field. When it comes to widespread diseases such as cancer, could AI be the tool we've been looking for to develop cutting-edge functional treatment?  Thomas Fuchs, a scientist in the groundbreaking field of Computational Pathology, sits down to enlighten us on this intriguing subject… Working with The Mount Sinai Health System, Thomas is interested in building AI models that can enhance cancer care and research. By looking at molecular differences in cancer cells, he believes that this will help predict the right treatment for patients.  Offer: TRĒ House products are crafted to bring you the best that legal, delivered-to-your-door THC has to offer. TRĒ House utilizes unique blends of carefully selected minor cannabinoids that get you lit in ways you've only ever dreamed of. TRĒ House offers an array of premium, legal THC products including gummies, vapes, prerolls, and more. Head over to trehouse.com and enjoy 30% off your order AND get a free Acapulco Gold HHC preroll when you use coupon code GENIUS. This offer expires August 31, 2023. In this podcast, you will learn about: The specific technology used to model images of cancer cells.  How it takes for sequencing results to come back to determine the status of cancer in patients. How AI is being used to improve different medical applications.  So, how does AI analyze and model diseases in the human body? Join the conversation to find out for yourself! To discover more about Thomas and his research, click here now! Episode also available on Apple Podcasts: https://apple.co/30PvU9C

Der Internetkonzern Google will neue Bilder von Straßen auf seinem Dienst Street-View einstellen. Wie man seine Daten schützen und Bilder pixeln lassen kann, erklärt der Datenschutzbeauftragte von Hamburg, Thomas Fuchs.

Treffen wir uns bald im Metaversum wieder? Bereits jetzt werden dort Grundstücke verkauft. Wird sich die Zukunft unseres Lebens im entgrenzten Raum der digitalen Welt abspielen? In einer neuen Realität? Mit einer neuen Identität? Aber ist ein digitales Leben ohne reale körperliche Interaktion überhaupt denkbar? Prof. Dr. Dr. Thomas Fuchs, Psychiater und Philosoph, Heidelberg Moderation: Dr. Johannes Lorenz, Katholische Akademie Rabanus Maurus, Frankfurt am Main Cover: © iStock

In this episode of "Ketchup with Dom Tomato," Dom sits down with Thomas Fuchs, a unicorn in the Parkour community who has been practising well into his 50s. They discuss his perspective on the balance between passion and security and how he's been able to pursue his passion for Parkour while still leading a balanced life. Thomas also shares his insights on how Parkour can benefit older adults and how his life coach experience has helped him inspire and motivate others. He talks about how parkour can be a valuable tool for personal growth and help build mental and physical resilience that translates to other areas of life. This episode is inspiring and motivational listen for anyone who wants to pursue their passion and to learn from someone who has successfully balanced passion with security.

Fipsi erreicht seine 100. Episode. Zu diesem festlichen Anlass stellen sich Alexander Wendt und Hannes Wendler mit ihrem Gast, Thomas Fuchs, die Frage danach, wohin die phänomenologische Psychopathologie strebt. Im Gespräch dem renommierten Psychiater thematisiert Fipsi dabei anspruchsvolle philosophische und wissenschaftsgeschichtliche Entwicklungstendenzen in der Psychopathologie. Hierbei steht immer wieder die Frage im Mittelpunkt, was die Phänomenologie zu den betreffenden Diskursen beisteuern kann. Fipsis Ziel ist es als erster Podcast seiner Art den Dialog zwischen Philosophie und Psychologie zu erschließen. Wir blicken mit Dankbarkeit auf die vergangenen 100 Aufnahmen. Wir bedanken uns herzlich bei allen Kolleginnen und Kollegen, mit denen wir hier diskutieren durften, bei Freunden und Familie, die uns stets unterstützten und motivierten und bei den Zuhörerinnen und Zuhörern, ohne die das ganze Projekt keinen Sinn haben würde.Auf YouTube finden Sie alle Episoden von Fipsi unter https://www.youtube.com/playlist?list=PLpIT6jK3mKTiQcXbinapKRbf39mLEpKWmAuf Spotify finden Sie Fipsi unter https://open.spotify.com/show/0il832RRDoPZPaNlC7vams?si=5KbdEcF1TImSHexKYGccfw&dl_branch=1Die Website der Arbeitsgemeinschaft: https://www.phi-psy.deMelden Sie sich mit Rückmeldungen und Anmerkungen gerne unter fipsi@phi-psy.deDiskutieren Sie mit uns auf Telegram: https://t.me/FipsiPPP oder https://t.me/PhiundPsyFür das Intro bedanken wir uns bei Estella und Peter: https://www.instagram.com/elpetera

Wir feiern Jubiläum: 100 Gespräche »einfach ganz leben«!»Herzlich willkommen zur neuen Folge von einfach ganz leben …« – so begrüßt Jutta Ribbrock alle zwei Wochen die Hörer:innen. Sagenhafte 100 Podcast-Gespräche hat sie seit Oktober 2018 geführt! Um dieses Jubiläum gebührend zu feiern, hat Jutta sich Podcast-Kollegin Kathie Kleff ins Studio eingeladen. Im Gespräch blickt Jutta zurück auf besondere Momente, inspirierende Begegnungen und erzählt, was der Podcast ganz persönlich in ihr angestoßen hat: Was ist ihre Lebensphilosophie? Was hat sie in den letzten vier Jahren gelernt? Welche Begegnungen haben sie am meisten beeindruckt? Wer inspiriert sie momentan besonders? Und natürlich: Was ist für Jutta persönlich Glück? Zum Weiterhören und Stöbern:juttaribbrock.deHörbücher gelesen von Jutta Ribbrock: www.argon-verlag.deJens Corssen, Thomas Fuchs und Jutta Ribbrock, Familienglück – Wie wir durch Anerkennung eine erfüllte Eltern-Kind-Beziehung erreichen (Buch und Hörbuch)www.kathiekleff.deGet happy! – Der Achtsamkeits-Podcast mit Kathie Kleff (Spotify)Im Gespräch werden diese Podcast-Episoden erwähnt: Erkenne deinen Selbstwert mit Sarah Desai (www.einfachganzleben.de)Mit Jens Corssen in 4 Schritten zum Erfolg (www.einfachganzleben.de)Veit Lindau über das Wunder in uns allen (www.einfachganzleben.de)Michael Curse Kurth über die Kraft guter Fragen (www.einfachganzleben.de)Die eigene Lebensgeschichte erzählen mit Rebecca Vogels (www.einfachganzleben.de)Mit Horst Lichter die Stille entdecken (www.einfachganzleben.de)Anastasia Umrik über Krisen als Chance (www.einfachganzleben.de)Franziska Schutzbach über die Erschöpfung der Frauen (www.einfachganzleben.de)Töchter für ein gleichberechtigtes Leben stärken mit Susanne Mierau (www.einfachganzleben.de)Die Titelmelodie dieses Podcasts findet ihr auf dem Album balance moods – Ein Tag in der Natur.Noch viel mehr Tipps zu einem bewussten Lebensstil findet ihr auf einfachganzleben.de.Besucht uns auch bei Facebook und Instagram.Weitere Podcasts von argon podcast gibt es unter argon-podcast.de.Ihr habt Fragen, Lob, Kritik oder Anmerkungen? Dann meldet euch auch gern per Mail: einfachganzleben@argon-verlag.deIhr könnt Jutta auch direkt schreiben: jutta@juttaribbrock.deUnd ihr findet sie bei Instagram Hosted on Acast. See acast.com/privacy for more information.

Genug Tobi und Kai Content. Endlich wieder eine Shuttletalk-Folge mit Gast. Thomas Fuchs, Communication Manager bei BadmintonEurope, erzählt wie es ihn ausgerechnet in die Medienwelt unserer geliebten Sportart verschlagen hat. Was sind seine Aufgaben in Europas Dachverband? Was muss sich in Zukunft verändern damit Badminton medial attraktiver wird? Wie sieht die Zukunft unserer Sportart aus? Und wie fühlt man sich wenn man Viktor Axelsen Interviewfragen stellt?

Der Hamburgische Beauftragte für Datenschutz und Informationsfreiheit (BfDI) steht stets im Fokus der Öffentlichkeit. Seiner Aufsicht unterliegen nicht nur die deutschen Niederlassungen von Meta (ehemals Facebook) und Google, sondern auch etliche große deutsche Medienhäuser, etwa der Springer-Konzern. Mit Spannung war daher im vergangenen Jahr erwartet worden, wer dem scheidenden, langjährigen BfDI Johannes Caspar folgen wird. Im November 2021 übernahm der Jurist Thomas Fuchs nach seiner Wahl durch die Hamburger Bürgerschaft das Amt. Fuchs war zuvor 13 Jahre lang Direktor der Medienanstalt Hamburg/Schleswig-Holstein. Er ist also im Bereich der behördlichen Aufsicht kein Unbekannter. In der aktuellen Episode 67 des c't-Datenschutz-Podcasts erzählt er von seinen ersten Monaten als oberster Hamburger Datenschützer. Fuchs betont, dass er einen kooperativen Ansatz seiner Behörde in den Vordergrund stellt. Datenschutz sei in den vergangenen vier Jahren vorwiegend als das "scharfe Schwert", die Drohung mit dem Bußgeld, wahrgenommen worden. Es gebe aber ein großes Bedürfnis nach demokratischer Datennutzung, etwa für Forschung und Mobilität: "Das möchte ich von Anfang an begleiten", betont Fuchs. Als Beispiel für verfehlte Regulierung nennt er die Pläne zu einem Impfregister: "Wir haben in der Coronapandemie brutalen Datenmangel. Viele haben gesagt, ein Impfregister geht datenschutzrechtlich nicht. Ich würde sagen: Das ginge sehr wohl datenschutzkonform, wenn klar geregelt würde, wer darauf zugreifen darf." Das Werk seines Vorgängers will Fuchs fortführen: "Wir beschäftigen uns weiterhin intensiv mit Meta und Google, und wir haben auch noch Einfluss auf die Entscheidungen, die allerdings in Irland getroffen werden." Fuchs ist guter Dinge, dass die irische Datenschutzbehörde als in der EU zuständige Aufsicht über die großen Tech-Konzerne gerade die Zügel anzieht. "Eine Entscheidung zur Datenübermittlung von Facebook in die USA steht beispielsweise unmittelbar bevor." Bauchschmerzen bereitet Hamburgs neuem BfDI die Ausformulierung der EU-Datenstrategie. Gesetze wie der Data Act oder der Data Governance Act seien zwar für sich genommen "spannend und relevant". Aber es sei "schlicht eine Katastrophe", dass sie keine Ausnahmen zur DSGVO enthalten, sondern komplett mit ihr in Einklang zu bringen sind: "Künftig dürften noch mehr Projekte gar nicht erst in Angriff genommen werden, aus Angst davor, irgendwie gegen Datenschutzrecht zu verstoßen." Die DSGVO müsse sich in einen Binnenmarkt einbetten, der auch Wirtschaftsinteressen berücksichtigt, sonst sei sie nicht zukunftsfähig.

Die 72. Folge des Podcasts Fipsi, der als erster seiner Art den Dialog zwischen Philosophie und Psychologie anstrebt. In dieser Episode diskutieren Hannes Wendler und Alexander Wendt über das Gehirn. In diesem Zusammenhang kommen sie unter anderem auf Gerhard Roth und Thomas Fuchs zu sprechen.Auf YouTube finden Sie alle Episoden von Fipsi unter https://www.youtube.com/playlist?list=PLpIT6jK3mKTiQcXbinapKRbf39mLEpKWmAuf Spotify finden Sie Fipsi unter https://open.spotify.com/show/0il832RRDoPZPaNlC7vams?si=5KbdEcF1TImSHexKYGccfw&dl_branch=1Die Website der Arbeitsgemeinschaft: https://www.phi-psy.deMelden Sie sich mit Rückmeldungen und Anmerkungen gerne unter fipsi@phi-psy.deDiskutieren Sie mit uns auf Telegram: https://t.me/FipsiPPP oder https://t.me/PhiundPsyFür das Intro bedanken wir uns bei Estella und Peter: https://www.instagram.com/elpetera

Nicolas Senn besucht nach der Skisaison das Restaurant Fuederegg in Oberiberg. Das Restaurant wurde erst kürzlich vom jungen Paar Melanie und Thomas Fuchs übernommen. Die beiden setzten mit ihrer Crew nicht nur auf die Gäste von der Skipiste, sondern haben auch im Sommer Grosses vor. Musikalisch sind Gäste aus der Region zu Gast. Zum Beispiel das Ländlertrio Moosbuäbä aus dem nahe gelegenen Euthal. Oder aus Unteriberg der schweizweit bekannte Schwyzerörgeli-Bauer Edgar Ott. Er wird bald pensioniert und möchte darum auch gerne selber wieder mehr Musik machen. Er spielt mit der IWAN MUSIG plus auf, mit Berufskollege, Klavierbauer Stefan Kessler, Iwan Meier und dem Pianisten Schöff Röösli. Ebenfalls aus dem Kanton Schwyz kommen Jörg Kenel und sein Sohn Fabian. Sie spielen als Echo vom Rufiberg zusammen mit Stefan Bürgler auf. Ebenfalls mit eigenem Nachwuchs kommt Hans Holderegger aus Hundwil AR. Die Familienkapelle Höhigruess besteht ausser ihm aus den Töchtern Claudia und Karin und Sohn Hansueli. Ebenfalls noch zur jungen Garde gehört das Ländlertrio Täktig aus dem Bernbiet. Peter Wüthrich, Manuel Kipfer und Jonas Vogel spielen im typischen Berner Örgelistil. Anlässlich des Schweizerischen Gesangsfest ist das Quintette des Barbus de Derrière les Fagots aus der Westschweiz zu Gast.

Die Play-Offs sind gestartet - Kocian, Gevert und Co stehen im Halbfinale für die Volleyball Bundesliga. Vor dem Heimspiel gegen den VfB Friedrichshafen hat Thomas Fuchs mit Helmut Schmitz, dem Mannschaftsbetreuer und Hallensprecher der Arena Kreis Düren, gesprochen.

Mit einer gesunden Portion Selbstvertrauen gehen Dürens Volleyballer in die Play-Offs. Vor dem Auftaktmatch sprach Thomas Fuchs mit Zuspieler Eric Burggräf.

Für den 28. Radio Rur SWD Powervolleys Podcast hat sich Thomas Fuchs mit Diagonalangreifer Filip John getroffen. Dürens Nummer 7 ist der Jüngste im Team, aber einer der Größten mit 2,04m.

Ivan Batanov ist bei den SWD Powervolleys Düren der Mann für Spezialaufgaben. Für den 27. Radio Rur SWD Powervolleys Podcast traf sich Thomas Fuchs mit dem erst 21-jährigen Libero.

Sebastian Gevert ist einer der besten Außenangreifer der Volleyball-Bundesliga. Für den Radio Rur SWD Powervolleys Podcast sprach Thomas Fuchs mit dem Linkshänder, der sich in Düren zuhause fühlt.

Michel Sorg est depuis 2020 le nouveau sélectionneur de lʹéquipe de Suisse de saut dʹobstacle. Avec Steve Guerdat, Martin Fuchs et Bryan Balsiger, il possède une équipe redoutable. Il peut également compter sur 23 autres cavaliers dans le cadre national et sur le meilleur entraîneur du monde en la personne de Thomas Fuchs. De quoi le rendre heureux mais de quoi lui mettre aussi un peu de pression sur les épaules, notamment ce week-end à Genève.

Das Medienprivileg ermöglicht z.B. Print-, TV- und Onlinemedien personenbezogene Informationen unter bestimmten Voraussetzungen für journalistische Zwecke zu verarbeiten. Medien können aber auch in ihren Aussagen selbst eine kritische Rolle für den Datenschutz spielen. Über beides sprechen wir mit Thomas Fuchs, dem Hamburgischen Beauftragten für Datenschutz und Informationsfreiheit.

Pflegeroboter, autonom fahrende Autos und beseelte Wesen – dies sind nur wenige von vielen spannenden Themen, die Schülerinnen und Schüler gemeinsam mit Experten in der letzten Folge der ersten Podcast-Staffel „Selbstbewusste KI“ diskutiert haben. Dabei kamen einige der Podcast-Gäste aus den vergangenen Folgen noch einmal zusammen, um mit den Schülerinnen und Schülern in einen Dialog auf Augenhöhe zu treten. Gesprächsgäste: Andreas Eschbach, Thomas Fuchs, Janina Loh, Thomas Metzinger, Ralf Otte, Christian Vater und Joachim Weinhardt Herausgeber: Karsten Wendland Redaktionelles Konzept: Tannaz Afshari Bakhsh, Franka Bockrath, Laura Müller, Anna Pallakst, Lea Riemann, Emma Rönnebeck, Eva Russow, Tamás Svajda und Renée Weisbach Moderation: Lara Wolf und Luis Tillmann Aufnahmeleitung: Karsten Wendland Produktion: Tobias Windmüller Feedback-Kanal: www.ki-bewusstsein.de/podcast Twitter: twitter.com/KIBewusstsein Licence: CC-BY Folgende weiterführende Quellen wurden in der Podcast-Folge genannt: Michael Chrichton: Prey, Harper Collins New York 2002. Leseprobe Fraunhofer Care-O-bot: Mobile Roboterassistenten zur aktiven Unter-stützung des Menschen im häuslichen Umfeld. TED-Talk von Kate Darling (MIT): Why we have an emotional connection to robots. TA-Swiss: Robotik in Betreuung und Gesundheitsversorgung, vdf Hochschulverlag 2013, S. 192. JürgenHabermas(1981): Theorie des kommunikativen Handelns. Band 2 Zur Kritik der funktionalistischen Vernunft. 8. Aufl. Frankfurt/a.M 1981. Martin Krammer: "Unser Schreibzeug arbeitet mit an unseren Gedanken". Beitrag der Universität Wien über Friedrich Nietzsche. Stefan Krempl: Ethikrat: Erosion von Verantwortung bei Robotereinsatz in der Pflege verhindern (Artikel bei Heise vom 11.03.2020). Thomas Fuchs: Verteidigung des Menschen. Grundfragen einer verkörperten Anthropologie, Suhrkamp 2020.

Chances are you or someone you love has had a biopsy to check for cancer. Doctors got a tissue sample and they sent it into a pathology lab, and at some point you got a result back. If you were lucky, it was negative and there was no cancer. But have you ever wondered exactly what happens in between those steps? Until recently, it's been a meticulous but imperfect manual process where a pathologist would put a thin slice of tissue under a high-powered microscope and examine the cells by eye, looking for patterns that indicate malignancy. But now the process is going digital—and growing more accurate.Harry's guest this week is Leo Grady, CEO of, Paige AI, which makes an AI-driven test called Paige Prostate. Grady says that in a clinical study, pathologists who had help from the Paige system accurately diagnosed prostate cancer almost 97 percent of the time, up from 90 percent without the tool. That translates into a 70 percent reduction in false negatives—nice odds if your own health is on the line. This week on the show, Grady explains explain how the Paige test works, how the company trained its software to be more accurate than a human pathologist, how it won FDA approval for the test, and what it could all mean for the future of cancer diagnosis and treatment.Please rate and review The Harry Glorikian Show on Apple Podcasts! Here's how to do that from an iPhone, iPad, or iPod touch:1. Open the Podcasts app on your iPhone, iPad, or Mac. 2. Navigate to The Harry Glorikian Show podcast. You can find it by searching for it or selecting it from your library. Just note that you'll have to go to the series page which shows all the episodes, not just the page for a single episode.3. Scroll down to find the subhead titled "Ratings & Reviews."4. Under one of the highlighted reviews, select "Write a Review."5. Next, select a star rating at the top — you have the option of choosing between one and five stars. 6. Using the text box at the top, write a title for your review. Then, in the lower text box, write your review. Your review can be up to 300 words long.7. Once you've finished, select "Send" or "Save" in the top-right corner. 8. If you've never left a podcast review before, enter a nickname. Your nickname will be displayed next to any reviews you leave from here on out. 9. After selecting a nickname, tap OK. Your review may not be immediately visible.That's it! Thanks so much.Full TranscriptHarry Glorikian: Hello. I'm Harry Glorikian. Welcome to The Harry Glorikian Show, the interview podcast that explores how technology is changing everything we know about healthcare.Artificial intelligence. Big data. Predictive analytics. In fields like these, breakthroughs are happening way faster than most people realize. If you want to be proactive about your own health and the health of your loved ones, you'll need to learn everything you can about how medicine is changing and how you can take advantage of all the new options.Explaining this approaching world is the mission of my new book, The Future You. And it's also our theme here on the show, where we bring you conversations with the innovators, caregivers, and patient advocates who are transforming the healthcare system and working to push it in positive directions.Chances are you or someone you love has had a biopsy to check for cancer. Doctors got a tissue sample and they sent it into a pathology lab, and at some point you got a result back. If you were lucky it was negative and there was no cancer.But have you ever wondered exactly what happens in between those steps?Well, until recently, it's been an extremely meticulous manual process. A pathologist would create a very thin slice of your tissue, put it under a high-powered microscope, and examine the cells by eye, looking for patterns that indicate malignancy. But recently the process has started to go digital. For one thing, the technology to make a digital scan of a pathology slide has been getting cheaper. That's a no-brainer, since it makes it way easier for a pathologist to share an image if they want a second opinion.But once the data is available digitally, it opens up a bunch of additional possibilities. Including letting computers try their hand at pathology. That's what's happening at a company called Paige AI, which makes a newly FDA-approved test for prostate cancer called Paige Prostate.The test uses computer vision and machine learning to find spots on prostate biopsy slides that look suspicious, so a human pathologist can take a closer look.So why should you care?Well, in a clinical study that Paige submitted to the FDA, pathologists who had help from the Paige system accurately diagnosed cancer almost 97 percent of the time, up from 90 percent without the tool.That translates into a 70 percent reduction in false negatives. At the same time there was a 24 percent reduction in false positives. I gotta tell you, if I were getting a prostate biopsy, I'd really like those improved odds. And it's a great example of the kinds of AI-driven medical technologies that I write about in The Future You, which is now available from Amazon in Kindle ebook format.So I asked Paige's CEO, Leo Grady, to come on the show to explain how the test works, how Paige trained its software to be more accurate than a human pathologist, how the company got the FDA to give its first ever approval for an AI-based pathology product, and what it could all mean for the future of cancer diagnosis and treatment.Here's our conversation.Harry Glorikian: Leo, welcome to the show.Leo Grady: Hi, Harry. Glad to be here.Harry Glorikian: Yeah. You know, I've been watching the company for some time now, and the big story here seems to be that we're really entering the area of digital pathology, also known as sort of computational pathology, and it's funny because I've been talking about digital pathology since I think I started my career back when I was 25, which seems like a long time ago at this point. But for a lot of laboratory tests that we use, like it's usually done by eye, and now we can get a lot from sort of AI being assistive in this way. So keeping in mind that some of the listeners are professionals, but we have a bunch of sort of non-experts, could you start off explaining the term maybe computational pathology and summarize where the state of the art is, which I assume you guys are right at the cutting edge of it?Leo Grady: Yeah, so I think it actually might help just to jump back a level and talk about what is pathology and how is it done today? So today, so pathology is the branch of medicine where a doctor is taking tissue out of a patient through a biopsy, through surgery and making glass slides out of that tissue, looking at it under a microscope in order to make a diagnosis. And today, all of that process of taking the tissue out, cutting it, staining it, mounting it on slides. Then gets looked at under a microscope by a pathologist to make a diagnosis, and that diagnosis the pathologist makes is the definitive diagnosis that then drives all of the rest of the downstream management and care of that patient. When pathologists are looking through a microscope, sometimes they see something that they're not quite sure what it is. And so they may want to do another test. They may want to do another stain. They may want to cut more out of the tissue, make a second slide. Sometimes they want to ask a colleague for their opinion, or if they really feel like they need an expert opinion, they may want to send that case out for a consultation, in which case the glass slides or are put in a, you know, FedEx and basically shipped out to another lab somewhere. All of those different scenarios can be improved with digital pathology and particularly computational pathology and the sort of technology that we build at Paige. So in a digital world, what happens instead is that the slides don't go to the pathologist as glass. They go into a digital slide scanner, and those slide scanners produce a very high resolution picture of these slides.Leo Grady: So these are quarter-micron resolution images that get produced of each slide. And then the pathologist has a work list on their monitor. They look through those those cases, they open them up and then that digital workflow, they can see the sides digitally. When they have those slides digitally, if they want to send them out to a second opinion or or show them to a colleague, it's much easier to then send those cases electronically than it is to actually ship the glass from one location to another. Once those slides are digital it, it opens up a whole other set of possibilities for how information can come to the pathologist. So if they want additional information about something they see in those slides, rather than doing another stain, doing another cut, sending for a second opinion, what we can do and what we do at Paige is we we identify all the tissue patterns in that piece of tissue, match those against a large database where we have known diagnoses and say, OK, this case, this pattern here has a high match toward to something that's in this database. And by providing that information to the pathologists on request that pathologists can then leverage that information, integrate it and use it in their diagnostic process. And this is the product that the FDA just approved. It's the first ever AI based product in pathology that is specifically aimed at prostate cancer and providing this additional information in the context of a prostate needle biopsy.Harry Glorikian: Well, congratulations on that. That's, you know, that's amazing. And I'm. You know, the fact that the FDA is being more aggressive than I remember them being in the past is also a great thing to see. But, you know, we've been talking and quote digitizing things in pathology for for quite some time, let's say, separate from the AI based analytics part of it moving in that direction. What was the kind of technology advance or prerequisite that you guys came up with when you started Paige that that took this to that next level.Leo Grady: Well, as you're pointing out, Harry, most slides are not digitized today, single digits of slides in a clinical setting get digitized. And the reason for that has been you need to buy scanners, you need to change your workflow, you need to digitize these slides. They're enormously large from a file size and data complexity. So then you have to store them somehow and you make all of that investment and then you get to look at the same slide on a monitor that you look at under a microscope. And so pathologists for years have said, why? Why would we make this investment? Why would we go through all of that expense? And that trouble and that change and learn a new instrument when we don't really get a lot of value out of doing so? And furthermore, there was even a question for a long time, do you get the same information on a digital side that you get on glass through a microscope? Yep. There have been a number of things that have been changing that over time. So one is the maturity of the high capacity digital side scanners. There are now a number of hardware vendors that produce these. Storage costs have come down. And one thing that we offer at Paige is is cloud storage, which is really low cost because we're able to effectively pool costs with the cloud providers from multiple different labs and hospitals, so we can really drive those prices down as far as possible.Leo Grady: So that lowers that barrier. And then back in 2017, the first digital side scanner got approved, which demonstrated there was equivalency in the diagnosis between looking at the slide on a monitor and looking at it under a microscope. And that is something that that we also replicated with our digital side viewer, demonstrated that equivalency between digital and glass. But all of those barriers were barriers just to going digital in the first place. And now, really, for the first time, because of the maturity of the scanners, because of the FDA clearance of just the viewer, because of lower cost storage, many of those barriers have come down. Now what has not happened is still a major clinical benefit for going digital in the first place. Yes, you can share slides easier. Yes, you can retrieve slides easier. Yes, you can do education easier. It's still a lot of cost and a lot of changed your workflow, so I really think that that the introduction of the kinds of technologies that that the FDA approved, which we built with Paige Prostate, that actually adds additional information into the diagnostic workflow that can help pathologists use that information help them. You get to a better diagnosis, reduce false positives, reduce false negatives, which is what we showed in the study that for the first time is is going above and beyond just going digital and some of these conveniences of a digital workflow to providing true clinical benefit.Harry Glorikian: Yeah, I mean, whenever I look at this from an investment perspective, like if you take apart something and break it into its first principles, you know, levels, you have to have certain milestones hit. Otherwise, it's not going to come together, right? And I've, you know, looking at digital pathology, it's the same thing. You have to have certain pieces in place for the next evolution to be possible, because it's got to be built on top of these foundational pieces. But, you know, once you get there, the exponential nature of of how things change, once it's digitized and once you're utilizing it and prove that it works is sort of where you see the, you know, large leaps of benefit for the pathologist as well as, you know, ultimately we're doing this for better patient care. But you know, your product was I think the FDA called it the first ever FDA approval for an AI product in pathology, which is a big deal, at least as far as I'm concerned, because I've been doing it for a long time. But because it was first, it must have been a one hell of a learning process for you and the FDA to figure out how to evaluate a test like this. Can you sort of explain maybe a little bit about the process? You know, how did you win approval? What novel questions did you have to answer?Leo Grady: It was a long process. You know, as you point out, this is this is the first ever technology approved in this space. And I think you saw from the FDA's own press release their enthusiasm for what this technology can bring to patient benefits. Fortunately, we applied for breakthrough designation back in early 2019, received that breakthrough designation in February of 2019. And as a result, one of the benefits of breakthrough designation is the FDA commits to working closely with the company to try to iterate on the study protocol, iterate on the the validation that's going to be required in order to bring the the technology to market. And so because of that breakthrough designation, we had the opportunity to work with the the FDA in a much tighter iterative loop. And I think that they are they were concerned, I mean, primarily about the impact of a misdiagnosis and pathology, right? Which is really understandable, right? Their view is that, yes, maybe in radiology, you see something and maybe aren't totally sure. But then there's always pathology as a safety net, you know, in case you ever really need to resolve a ground truth. You can always take the tissue out and look at it under a microscope. But when you're dealing with a product for pathology, that's the end of the road. I mean, that is where the diagnostic buck stops. And so anything there that that was perhaps going to misinform a pathologist, mislead them, you know, ultimately lead to a negative conclusion for the patients could have more severe consequences.Speaker2: The flip side, of course, though, is that if you get it right, the benefits are much greater because you can really positively impact the care of those patients. So I think they they, you know, appropriately, we're concerned with the exacting rigor of the study to really ensure that that this technology was providing benefit and also because it was the first I think they wanted to be able to set a standard for future technologies that would have to live up to the same bar. So there were a lot of meetings, you know, a lot of trips down to Silver Spring. But I have to say that that the FDA, you know, I think in technology, there are a lot of companies that are are quick to, you know, malign regulators and rules. I frankly both at Paige and my previous experience at HeartFlow, at Siemens, I think the FDA brings a very consistent and important standard of clinical trial design of of, you know, technology proving that is safe and effective. And I found them to be great partners to work with in order to really identify what that protocol looks like to be able to produce the validation and then to, you know, ask some tough questions. But that's their job. And I think, you know, at the end of the day, the products that get produced that go through that process really have met the standard of of not only clinical validation, but even things like security and quality management and other really important factors of a clinical product.Harry Glorikian: Oh no, I'm in total agreement. I mean, whenever I'm talking to a company and they're like, Well, I don't know when I'm going to go to the agency, I'm like, go to the agency, like, don't wait till the end. Like there, actually, you need to look at them as a partner, not as an adversary.Leo Grady: Yeah. And a pre-submission meeting is is easy to do. It's an opportunity to make a proposal to the FDA and to understand how they think about it and whether that's that's going to be a strategy that's going to be effective and workable for them. So I always think that that pre subs are the place to start before you do too much work because you generally know whether you're on the right path or not.Harry Glorikian: Yeah, I agree. And it's funny because you said, like, you know, they're concerned about the product, but it's interesting. Like from all the College of American Pathology studies where you send slides to different people, you don't always get the exact same answer, depending on who's looking at it. So I can see how a product can bring some level of standardization to the process that that helps make the call so uniform, even across institutions when you send the slides. So I think that's moving the whole field in a really positive direction.Leo Grady: Well, only if that uniform call is correct, right? Or better? Great. I mean, if you bring everybody down to the lowest common denominator that that standardization, but it's not moving the field forward. So. Correct. One of the curses of of bringing that level of standardization is that you have to really meet the highest bar of the highest pathologists and not not just the average. That said, you know, we're fortunate to come from Memorial Sloan-Kettering and to have the opportunity to work with some of the the leading pathologists in the world to really build in that level of rigor and excellence into the technology.Harry Glorikian: Yeah. So that brings me to like, you know. The algorithms are built on a fairly large training set would be my assumption and of pre labeled sort of images, where do you guys source that from? Is it you have like a thousand people in the background sort of making sure that everything is labeled correctly before it's fed to the to the algorithm itself?Leo Grady: Well, what you're describing is very common where you have pathologists or in radiology radiologists or other experts really marking up images and saying this is the important part to pay attention to. This part is cancer. That part's benign. Our technology actually works differently. Our founder, Thomas Fuchs, and his team at Memorial Sloan-Kettering actually really made a breakthrough not only in the the quality of some of the the AI systems that were building, but also in the technology itself. And what what they did, this was all published in Nature Medicine a couple of years ago, is basically find a way to just show the computer a slide and the final diagnosis without having a pathologist, you know, mark up the slide, but just show them the final diagnosis. And when you show the computer enough examples of the slide and the final diagnosis, the computer starts to learn to say, OK, this pattern is common to all grade threes. This pattern is common to all grade fours. Or whatever it is. And the computer learns to identify those patterns without anybody going through and marking those up. Well, this technology is important for a few reasons.Leo Grady: One, it means we can train systems at enormous scale. We can not just do thousands of cases, but tens of thousands, hundreds of thousands of cases. Second, it means that we can really build out a portfolio of technologies quickly that are very robust and not have to spend years annotating slides. And third, it allows us to start looking for patterns that no pathologists would necessarily know how to mark up. You know, can we identify which tumors are going to respond to certain drugs or certain therapies? You know, no pathologists are going to be able to say, OK, it's this part of the the tumor that you need to look at because they don't really know. But with this technology where we we know these tumors responded, these tumors didn't it actually helps us try to ferret out those patterns. So that that's one of the real key benefits that differentiates Paige from from other companies in this space is just the difference in the technology itself.Harry Glorikian: Yeah. I mean, it's funny because I must admit, like when we talk about stuff like this, I get super excited because I can see where things can go. It's. It's always difficult to explain it where somebody else can envision what you've been thinking about because you've been thinking about it so long, but it's super exciting. So let's jump to like the most important benefits, like if you had to rank the benefits of the technology, I mean, I've I read on your website that in the clinical study you guys submitted to the FDA, pathologist used using the Paige Prostate were seven percent more likely to correctly diagnose the cancer. Is that the major innovation? Would that by itself be enough to justify an investment in the technology? I mean, I'm trying to. You know, if you were to say God, this is the most important thing and then go down the list, what would they be?Leo Grady: Yeah, that's right. So so the study that we did was like this. We had 16 pathologists. They diagnosed about six hundred prostate needle core biopsy patients and they they did their diagnosis. They recorded it and then they did it a second time using Paige so they could see the benefit of all this pattern matching that that Paige had done for them. And what we did is we compared the diagnosis. They got the first time and the second time with the ground truth, consensus diagnosis that we had from Memorial. And what we found is that when the pathologists were using Paige, they had a 70 percent reduction in false negatives. They had a 24 percent reduction in false positives, and their interest in obtaining additional information went down because they had more confidence in the diagnosis that they were able to provide. And what was interesting about that group of 16 pathologists is it it included pathologists that were experienced, that were less experienced, some that were specialists in prostate cancer, some that were not so specialized in prostate cancer. And among that entire group of pathologists, they all got better. They all benefited from using this technology. And what's more, is that the gap between the less experienced, less specialized pathologists and more experienced, more specialized pathologists actually decreased as they all used the technology. So it allowed them to, like we were talking about before, actually come up to the level of of the better pathologists and even the better pathologists could leverage the information to get even better.Harry Glorikian: So as a male who you know who's going to age at some point and potentially have to deal with, hopefully not, a prostate issue, we want them to make an accurate diagnosis because you don't want the inaccurate diagnosis, especially in in that sort of an issue. But what about the speed? I mean, you've you talk about that, you know, it helps streamline the process and reduce reduce turnaround time for for patients. What does that do to workload and and how quickly you're able to turn that around compared to, say, a traditional method.Leo Grady: Our study was really focused on clinical benefit and patient benefit. We were not aiming to measure speed and the way in which the study was designed and the device is intended to be used is that the pathologist would look at the case, decide what they they think the result is, and then pull up the Paige results and see if it changes their thinking or calls their attention to something that they may have missed. So the focus of the the product was really on the the benefit to the the clinical diagnosis and the clinical benefit to patients by providing more information to the doctors. And the result of that information was, you know, clearly demonstrated benefit. Now if they can get to that result by looking at the Paige results and they don't need another cut, they don't need another stain, they don't need another consultation, then that's going to get the results back to the urologists faster, back to the patient faster and will ultimately enable them to start acting on that diagnosis more quickly. But the intention of the study, the intended use of the device is not around making pathologists faster. It's really around providing them this additional information so that they can use that in the course of their diagnosis and get the better results from patients.[musical interlude]Harry Glorikian: Let's pause the conversation for a minute to talk about one small but important thing you can do, to help keep the podcast going. And that's to make it easier for other listeners discover the show by leaving a rating and a review on Apple Podcasts.All you have to do is open the Apple Podcasts app on your smartphone, search for The Harry Glorikian Show, and scroll down to the Ratings & Reviews section. Tap the stars to rate the show, and then tap the link that says Write a Review to leave your comments. It'll only take a minute, but you'll be doing us a huge favor.And one more thing. If you like the interviews we do here on the show I know you'll like my new book, The Future You: How Artificial Intelligence Can Help You Get Healthier, Stress Less, and Live Longer.It's a friendly and accessible tour of all the ways today's information technologies are helping us diagnose diseases faster, treat them more precisely, and create personalized diet and exercise programs to prevent them in the first place.The book is now available in Kindle format. Just go to Amazon and search for The Future You by Harry Glorikian.And now, back to the show.[musical interlude]Harry Glorikian: So I asked this out of naivete because I didn't I didn't go looking for it. But have you guys done a health economic analysis of the system?Leo Grady: We have one. It certainly it's, as you know, it's really key to be able to look at that we have a model that we've built. We're still refining it with additional data. There was a study that was announced in the U.K. a couple of weeks ago where the NHS is actually funding a prospective multicenter trial that includes Oxford, Warwick, Coventry, Bristol to be able to evaluate the the health, economics and clinical benefits of using this technology in clinical practice prospectively. So that's something that we engaged with NICE [the National Institute for Health and Care Excellence] on in order to try to get the design correct that will help feed in real world data into the model. But we have a model that we've been using internally and are continuing to build and refine.Harry Glorikian: So. Again, incredible that you guys got FDA approval, I think the company was founded in 2017, if I'm correct. Can you talk about, you know, the founders and yow you guys, you know, built this so quickly, I mean time scale wise, it's a pretty compressed time scale, relatively speaking.Leo Grady: Well, yeah, it isn't, it isn't, ...so the company started in 2017, our first employee was actually middle of 2018 and we had our first venture round and in early 2018. However, the work that went into the company that spun out of Memorial Sloan-Kettering started earlier. So there is a group of really visionary individuals at MSK that back, I want to say, 2014, 2015, actually had started this push toward digital pathology, computational pathology, really seeing where the puck was going and building this technology. They formed something called the Warren Alpert Center, and the Warren Alpert Center provided some initial funding to really get this going and to hire some of the founders and to really move this technology in the right direction. And it was really because that technology started to show such promise that MSK made the decision that that was at a point where it could be better, you know, more impactful to actually go outside of MSK into a company where where we could industrialize the technology and really bring it to hospitals and labs around the world. So the technology started earlier, 2014, 2015. Paige was really launched in, I would say, 2018, although technically it was incorporated earlier and and then from that point I personally joined in 2019. And so I'm not I'm not a founder, but when I joined in 2019, you know, we we really spun up a significant team and and brought to bear some of my own experience and industrializing AI technology and bringing it out to clinical benefit.Harry Glorikian: Well, you know, most founders don't take the company all the way. It's a rare breed that's able to get it that far. So you know this a great story, but let's step back here and talk about like now you have to like, get people to accept this technology right, which is the human factor which I always find much more confounding than the the the the computational factor. So you've got to get, you know, somebody inside a hospital or pathology lab. Do you run into resistance or pushback from the technology, I mean, are they skeptical about the algorithm? How do you get a human to sort of buy off on this? I remember when we were presenting this, oh God, again, 25 years ago, they hated it. I mean, just hated it. And as time has gone by, you've seen that that digitization is slowly taking effect and where you know, it's assistive as opposed to something, I remember when we first launched this, it was, "This is going to be better than" or "take your job," which is a great way to make an enemy on the other side. And I see that the two actually being better than one or the other per se on on its own. So how are you guys approaching this? And do you have any anecdotal stories that you might be able to share?Leo Grady: Yeah, and so I think there are two elements are one is, you know. Are people resistant by the nature of the technology because they feel threatened by it, and then the other is how does market adoption start with this sort of technology to just the first point? You know, I tend to be very careful about the term AI. I feel like it know it often introduces this concept of, you know, people think of a robot doctor that's going to run in and start doing things. And it's just it's not. I mean, AI is a technology that's been in development for four decades. I did my PhD in AI, in computer vision, 20 years ago, and it's just a technology, right? It's like a transistor. It can be used to build many different things. At its core, it's just complex pattern matching, which is what we how we leverage that technology. In the case of Paige Prostate was to help provide that information. I think, you know, the better frame to think about this technology is as a diagnostic. This is just like a diagnostic test. You validate it with a standalone sensitivity and specificity. The information gets provided the doctor. You have to do a clinical trial that samples the space effectively of the patient population and the intended use.Leo Grady: And you have to make sure the doctors understand the information and know how to use it effectively. It's before my time, but I heard that when immunohistochemistry was first really introduced in pathology, that there is a discussion that this was going to take all the pathologists' jobs. And who needs a pathologist if you can just stain with IHG and get get a diagnostic result out of it? Well, you know, 20 years, IHT is an essential component of of pathology, and it's a key element of of the diagnostic workflow for pathologists. So, far from replacing any pathologists, it's empowered them. It's made there the benefit that they can provide to the clinicians, even more valuable and even more important. And I think we're going to see a similar trajectory with this computational technology. Now your first question about market adoption, how people adopting this, I would say that, you know, last week I went to the College of American Pathology meeting, which was in person in Chicago. It's my first in-person meeting since COVID, so a year and a half ago. And I noticed--and this was this was right after the announcement by the FDA of of the approval for Paige Prostate--I noticed there was a market shift in the conversations I was having with pathologists.Leo Grady: It was a shift away from "Does this technology work? Is it ready for prime time? What does it really do?" Toward, "Ok, how do we operationalize this? How do we bring it in house, how do we integrate this into a workflow and how do we how do we pay for it?" You know, those are the conversations that we were having in Chicago at CAP. Not does this work? Is it ready for prime time? So I do think that there is a market understanding that the technology is real, that it works, that it can provide benefit. Now it's just a question of how do we operationalize and how do we get it paid for? Because today there's no additional reimbursement for it. But you know, again, with market adoption, you're got your Moore adoption curve for anything. You get them and you get your innovators and early adopters, your early majority, late majority and your laggards. And you know where I think we're at a stage where we've got innovators and early adopters that are excited to jump in and start leveraging this technology. And I think, you know, we're going to get to your early majority and the late majority over time. It's always going to be a process.Harry Glorikian: Yeah, no. I mean, you know, reflecting on your IHC [immunohistochemistry], that's where I started my career. Like, I think I taught like two hundred and fifty IHC courses over the first, say, three or four years that I was in the in the business. Three or four years. And you know, I agree with you. There's no way that any one of these technologies takes the place of [a pathologist]. They're additive, right? It's just a tool that helps. Make the circle much more complete than it would be in any one component, all by itself.Leo Grady: Could you ever hear when you were teaching these classes? Did anyone ever say that like, are we even going to need pathologists anymore?Harry Glorikian: No, it was when the is is when imaging systems came out that said the imaging system would then replace the pathologists. The IHC was was really the cusp of precision medicine, where I remember when I first started because we were working with ER and PR and, you know, when I first learned, you know about like, you know, the find and grind method, I would always be like, OK, it's x number of femtomoles. Like, What does that really telling you, right? Compared to this stain over here where I can see, you know, the anatomy, I can see where the cells are. I can see. I mean, there's so much more information that's coming from this that lets me make a better call. I will tell you selling it was not that hard to a lot of people, they they could see the benefit and you could you could really sort of get them to adopt it because they saw it as a tool.Leo Grady: Was that post-reimbursement?Harry Glorikian: Uh, even pre-reimbursement.Leo Grady: Really interesting. Yeah, there's there's a lot we can learn from you then.Harry Glorikian: Yeah, it was. It was. It was an interesting ride back then. I mean, I remember my first day at work. My boss comes to me and says. By the way, you're going to give a talk in Arizona in two weeks, and I was like, What do you mean I'm going to go? Who am I going to give a talk to you? He goes, Oh, you got to give a talk on the technology and how to use it. And I said, who's in the audience? And he said histo techs, and there'll be some pathologists. And I was like, Are you kidding me? And he goes, You got two weeks to get ready. Oh my God, I was cramming like crazy. I was in the lab. I was doing all the different types of assays that we had available. And you know, it was you went out there and I learned very quickly like, the show must go on, like you got to get out there and you got to do your thing. But it was it was a great time in my career to be on that on that bleeding edge of what was happening. So quickly, like, why did you guys start with prostate cancer, though like? It's not the most common cancer, although it's high on the list, so. Or maybe it's the second most type of cancer, but why did you guys start with that and where do you guys see it going from there, I guess, is next.Leo Grady: Well, the the decision of how to rank the different opportunities for, you know, ultimately we believe this technology can benefit really the entire diagnostic process, no matter what the question is in pathology. However, we did have to prioritize right and elements of of where to start, right. The elements of prioritization had a few factors. So one factor was how how prevalent is the disease? I mean, as you know, prostate cancer is one of the big four. Second, is there are a lot of benefit that we can provide today with prostate cancer. You know, man of a certain age goes in, gets a PSA test. It's high, they go and they get 12 cores, 14 cores, 20 cores out of their prostate and that produces. You know, it can be 30 slides, it can be 50 slides, I mean, it really depends, and this can take the pathologist a long time to look through. Most of those cores are negative. In fact, most of those patients are negative, but the consequence of missing something is really significant. And so we felt that this was a situation where there was a big need. There's a lot of there's a lot of screening that goes on with prostate cancer. Prostate cancer is prevalent and the consequence of missing something is really significant. So that's where we felt like we could provide maximum benefit, both in terms of the patient, in terms of the doctor, and also that it was a significant need across the space.Leo Grady: We also had the data and the technology that we could go after that one well. But that said, you know, we announced that we have a breast cancer product that is got a CE mark in an enabling clinical use in Europe. We're doing a number of investigational studies with that product in the US right now and and working toward bringing that one to market. You know, after our our recent funding round, we spun up a number of teams and a number of of verticals that were we're going after in other cancer types and ultimately even beyond cancer. So there's more to come. We wanted we really take seriously the quality, the regulatory confirmation as well as the deployment channel. I mean, we built the whole workflow to be able to leverage this technology throughout the workflow in a way that is meaningful to the pathologist. So the development is is maybe a little bit more heavy and validation than some other companies where you have a PhD student that says, Oh, you know, I won some challenge and I went to go bring this to market building real clinical products, validating them, deploying them, supporting them is a real endeavor. But prostate was just the first, breast is second, and we have a whole pipeline coming out. So stay tuned.Harry Glorikian: So before we end here, I want to just tilt the lens a little bit towards the consumer and say, like, you know. Why would consumers show interest or at least be aware that these things are coming? Because I always feel like they're almost the last to know, or they just don't know at all. But, you know, in the future, you know, with technologies like this, do you see it identifying tumors sooner, faster, more accurately? Or, you know, will it will it help increase survival or help us find better drugs? I mean that that's I think, what people are really... If you went down one level from us of the people that are affected by this. Those are the sorts of things they'd want to know.Leo Grady: Well, I think, you know, a useful analogy is what happened with the da Vinci robot. You know, when it was necessary for a patient to get prostate cancer surgery, they often chose centers that had the da Vinci robot. Why? Because they believed that they were able to get better care at those centers. And it's not because the surgeons at the other centers were no good. It's because the the da Vinci added elements of precision and standardization and accuracy that could be demonstrated that would enable the the patient to feel more confident they're getting the best treatment at those centers. So as I think about Paige Prostate and and ultimately the other technologies that we're bringing to market behind that, I would imagine that from the standpoint of the patient, they would want the diagnosis done at a lab where they had access to all of the available information, all the latest technology that could inform the pathologists to get the right answer, right? So would you want to go to a lab where the pathologists had no access to IHC? Would you want to send it to a lab where the pathologist had no ability to do a consultation? Do you want to send your your sample to a lab where the pathologist doesn't have access to Paige? I think in the future the answer is going to be no.Leo Grady: And I think that we're going to see ultimately, insurance companies and Medicare recognize that those labs are able to provide better care to patients and are going to encourage them and incentivize them to adopt these technologies. So, you know, ultimately from a patient standpoint, they they want to choose centers where they're going to get the best care, they're going to get the best diagnosis. I think one of the exciting elements of digital technology is that not everybody is able to go to Memorial Sloan-Kettering, not everyone's able to go to MD Anderson or Mayo Clinic. I think the opportunity with digital technology is to really increase the accessibility and increase the availability of these diagnostic tools that can really empower and enable pathologists in many parts of America, as well as beyond to really get to better results for their patients. And ultimately, you know, every patient cares about getting those those results accurately for themselves and for their loved ones.Harry Glorikian: Yeah, I mean, I'm always explaining, you know, to different people like once you digitize it, there's so many opportunities that may open up to make things better, faster, easier, more accurate and even start to shift the business model itself of what can be done and where it can be done. So it's it's a super exciting space, and thanks for taking the time. It was great to talk to you. I mean, I don't get to talk to people in pathology all the time anymore. I'm sort of all over the place, but it's it's near and dear to my heart, that's for sure.Leo Grady: Well, thank you so much, Harry. We're so excited by these recent developments with the first ever FDA approved technology in this space and, you know, really excited to help roll this out to labs and hospitals around the country and around the world to really benefit those doctors and patients.Harry Glorikian: Excellent. Well, I look forward to hearing about the next FDA approval.Leo Grady: Working on it. Look forward to telling you.Harry Glorikian: Thanks.Leo Grady: All right. Thanks so much, Harry.Harry Glorikian: That's it for this week's episode. You can find past episodes of The Harry Glorikian Show and MoneyBall Medicine at my website, glorikian.com, under the tab Podcasts.Don't forget to go to Apple Podcasts to leave a rating and review for the show.You can find me on Twitter at hglorikian. And we always love it when listeners post about the show there, or on other social media. Thanks for listening, stay healthy, and be sure to tune in two weeks from now for our next interview.

Verhaltenstherapeut und Coach Jens Corssen über erwachsene Beziehungen, gemeinsame Abenteuer und sein Konzept des Selbst-Entwicklers

Verhaltenstherapeut und Autor Dr. Thomas Fuchs darüber, wie ein glückliches Leben mit Kindern gelingt und warum dabei Anerkennung so wichtig ist

Keine Kontakte, keine Berührungen, persönliche Konversation nur mit Maske - die Corona-Pandemie setzt der Seele zu. Was macht der Ausnahmezustand mit uns? Antworten im Samstagsgespräch mit dem Psychiater Thomas Fuchs.

Im Corona-Jahr ist auch bei den SWD-Powervolleys vieles anders. Bis jetzt gibt es im gesamten Team aber noch keinen positiven Corona-Fall. Thomas Fuchs mit allen aktuellen Infos!

Die ersten Spiele der Saison sind unter Coronabedingungen durchgeführt worden. Thomas Fuchs zur aktuellen Lage bei den Dürener Volleyballern.

Über seinen Haarföhn, Essen im Restaurant und Provokationen: Thomas Fuchs (SVP) zu Gast im Wahlspezial des Podcasts BZ us dr Box.

Thomas Fuchs bildet sich nebenberuflich bei OTL zum Fitnesstrainer weiter und trainiert bereits erfolgreich seine eigenen Kunden. Über seine weiteren Pläne und seine ersten Erfahrungen als Personal Trainer spricht er im Interview mit Moderator Niklas Brose. Web: otl.gmbh Instagram: www.instagram.com/onlinetrainerlizenz Facebook: www.facebook.com/onlinetrainerlizenz Blog: otl.gmbh/blog

Äußerungen zu politischen Themen von Influencern werden zunehmen, meint Thomas Fuchs, Direktor der Landesmedienanstalt Hamburg Schleswig-Holstein: "Deswegen glaube ich, dass wir dringend Regeln für politische Werbung auf Social Media brauchen."

Thomas Fuchs über den Start in die Volleyballsaison 20/21

Bewusstsein im Computer ist eine Simulation, sagt Prof. Dr. Dr. Thomas Fuchs, Inhaber der Karl-Jaspers-Professur für Philosophische Grundlagen der Psychiatrie und Psychotherapie an der Universität Heidelberg, in der ersten Folge unseres Podcasts Selbstbewusste KI. Sein aktuelles Buch “Verteidigung des Menschen“ ist kürzlich bei suhrkamp erschienen. Fragensteller in dieser Folge: Murad Futehally, Mumbai/Ettlingen Autor: Karsten Wendland Redaktion: Tobias Windmüller Aufnahmeleitung und Produktion: Konstantin Kleefoot Feedback-Kanal: www.ki-bewusstsein.de/podcast Twitter: twitter.com/KIBewusstsein License: CC-BY, DOI: http://doi.org/10.5445/IR/1000123619

Der Mensch ist nicht nur Hirn. Das (Selbst-)Bewusstsein der Menschen entsteht immer mit und durch einem lebendigen Körper, sagt der Heidelberger Philosoph und Psychiater Thomas Fuchs. Damit fehlten künstlicher Intelligenz und menschenähnlichen Robotern wichtige Merkmale des Menschen. Fuchs These: Wir verlieren Menschlichkeit, wenn wir Menschen nach dem Modell von Maschinen verstehen. Rezension von Christoph Fleischmann. Suhrkamp Verlag ISBN 978-3-518-29911-1 336 Seiten 22 Euro

Willkommen zur ersten Podcast Folge!Im Interview treffe ich mich mit Herrn PD Dr. Thomas Fuchs, welcher als Chefarzt für Orthopädie und Unfallchirurgie seit 2016 das Muskuloskelettale Zentrum am Vivantes Klinikum Friedrichshain (Berlin) leitet.Ich wünsche viel Spaß beim Zuhören.

Corona und die Psyche - dieses Thema erläutert WDR 5 Moderator Ralph Erdenberger mit dem Philosophen und Psychiater Thomas Fuchs.

Já faz algum tempo que o Vinícius e eu denominamos de conjunto mente-cérebro à dupla dinâmica e indissociável formada pela mente, pelo cérebro e pelo fosso existente entre eles Nesse episódio conversamos sobre a proposta de Thomas Fuchs, professor catedrático da clínica psiquiátrica da Universidade de Heidelberg, na Alemanha, sobre o desenvolvimento e as funções do cérebro, apresentada no livro “Ecology of the brain”, de 2018. Ele diz que a fenomenologia é a via para compreensão da singularidade de cada indivíduo, mas incorpora nessa visão os conhecimentos derivados dos avanços da neurociência.

Coach und Expertin für Persönlichkeitsentwicklung Sigrid Engelbrecht über ein sinnstiftendes und zufriedenes Leben

***** Hat Dir diese Podcast Folge gefallen? Wenn ja, würde ich mich über eine 5* Bewertung sehr freuen. Hast Du den Podcast bereits abonniert? Nein? Dann abonniere jetzt den Podcast auf deiner Lieblings-Plattform! ***** Über Thomas Fuchs: Mein Name ist Thomas Fuchs und ich helfe Neu-Unternehmern dabei, ihr persönliches Herzschlag-Business zu entwickeln. Ein Business, für welches dein Herz schlägt. Ein Business, wofür du brennst und dass nachhaltig und erfolgreich-stabil ist. Und eines, dass mit Online Marketing Technologien unterstützt wird, damit du deine Qualitäts Lebenszeit zurück gewinnst. Ich betreue meine Kunden mit Sinn, Herz und was mir ganz wichtig ist: persönlich in 1:1 Gesprächen Doch bis mir selbst klar wurde, dass dies genau mein eigenes Herzschlag-Business ist, habe ich viele Fehler gemacht. Die ersten zwei Jahre meiner Unternehmensgründung waren ein teilweise wilder Ritt durch Online Technologien. Ich habe sehr viel Zeit und Geld investiert in meinen Unternehmensaufbau und nicht alles davon war eine gute Investition. Welche Fehler das waren und wie ich heute meinen Kunden dabei helfe, genau diese zu vermeiden, erfährst du in meinem persönlichen Ratgeber. Ein echtes Premium Dokument - für dich kostenlos zum Download auf https://herzschlag-business.com ******** MEHR von David Hahn & deiner digitalen Immobilie findest Du hier: Dein Gratis Ratgeber + täglicher E-Mail - Warum 98,7 % aller Webseiten kein Geld (im Internet) verdienen hier: https://www.seo-galaxy.com/p-ratgeber Gratis DIGITALE IMMOBILIEN Facebook Gruppe: https://www.seo-galaxy.com/p-fbgruppe Digitale Immobilien Membership 7 Tage für nur 1 € testen hier: https://www.seo-galaxy.com/p-di-membership Dein 45 minütiges Klarheits-Gespräch mit mir persönlich hier: https://www.seo-galaxy.com/p-klarheit *****

VideoYouTubeOur SponsorTrackJSJavaScript breaks sometimes. Even the code you write. You need to know when things start crashing in production.TrackJS Front-End Monitoring quickly integrates with your front-end or node application, regardless of framework, so you know when a bug gets out. TrackJS installs in minutes, and you get context about what the user, network, and application were doing before an error. It's like having an airplane's blackbox in your UI, so you can find, recreate, and fix problems fast.TrackJS is an engineer-owned cloud service that will make your JavaScript better and your website more reliable. Try it free at TrackJS.com.Today’s GuestChris Ferdinandi@ChrisFerdinandiWelcome, Script & Style listeners! | Go Make ThingsYour HostsDavid Walsh@davidwalshbloghttps://davidwalsh.nameTodd Gardner@toddhgardnerhttps://todd.mnEpisode SummaryVanilla JavaScriptChris Ferdinandi is a Frontend developer and advocate for Vanilla JavaScript. He runs GoMakeThings, a JavaScript learning platform.Chris’s Origin Storyhttps://gomakethings.com/The HR Guy who knows TechMaking things that run in a browser was a thrillWhy should people learn vanilla JavaScript over React, Angular, Vue, Etc.?Tell us about the Lean Webhttps://leanweb.dev/Thomas Fuchs coined term, “The LeanWeb”This was a tweet that turned into some blog posts that turned into a talk that turned into an ebook and site.Key thesis: The web is a bloated, over-engineered mess, and many of our modern “best practices” are actually making the web worse.Key principles: Embrace the Platform, Small & Modular, and The Web is for Everyonehttp://youmightnotneedjs.com/https://vanillajstoolkit.com/

Thomas Fuchs vom Deutschen Wetterdienst berichtet im Gespräch mit dem Behörden Spiegel über Extremwetterlagen und deren Auswirkungen für Deutschland. Außerdem werden die Rahmenbedingungen für den Katastrophenschutz ausgeführt. Die heraufbeschworene Sorge einer Rezession der deutschen Wirtschaftsleistung wird im Kommentar kritisch hinterfragt. Abschließend widmet sich die Recherche den Einsatzmöglichkeiten von KI im digitalen Rathaus der Zukunft und wägt die Chancen und Hürden ab.

PAL-Verleger*innen Maja und Carlo Günther über rauschende Feste, inspirierende Kontakte und alltägliche Glücksmomente

Hass lässt sich als eine anhaltende affektive Gesinnung auffassen, die auf eine erlebte Kränkung und Ungerechtigkeit zurückgeht und auf Rache an ihrem Urheber, in extremen Fällen auf die Vernichtung des »Todfeindes« ausgeht. Die besondere Dynamik und Gefährlichkeit des Hasses resultiert aus der Affektverhaltung, die durch die empfundene eigene Schwäche oder Ohnmacht des Hassenden bedingt ist. Gerade dieser Rückstau lässt den Hass sich in der Latenzphase immer weiter nähren, solange bis er schließlich in akute destruktive Handlungen umschlagen kann. Diese individuelle Dynamik findet sich in oft potenzierter Form im Hass von Gruppen wieder, der auf soziale und politische Kränkungserfahrungen zurückgeht. Der Vortrag untersucht die Phänomenologie des Hasses und die daraus resultierende Form von Destruktivität anhand literarischer Beispiele (Kohlhaas, Ahab), psychischer Störungen (Verbitterungssyndrom, Amoklauf ) und gesellschaftlicher Phänomene (Terrorismus).

Fusionieren Vodafone und Unity Media tatsächlich, dann wird das die Medienlandschaft nachhaltig verändern. Fernsehanbieter hätten de facto nur noch zwei Verhandlungspartner im Kabelmarkt: Vodafone und Telekom. Was das auch für den Nutzer bedeutet, darüber spricht Thomas Fuchs von der Medienanstalt Hamburg/Schleswig-Holstein in diesem Podcast.

Grüsse an Daniel DRF Frey von: Anna Rosenwasser, Beatrice von der AHB und Veronika Minder, Christoph Janser, Florian Vock, Henry Hohmann, Lovis Cassaris, Max Krieg, Patrick Rohr, Peter Gabriel Maria Christen, Selma, Thomas Fuchs, Udo Rauchfleisch, Wuddri Rim

Grüsse an Daniel DRF Frey von: Anna Rosenwasser, Beatrice von der AHB und Veronika Minder, Christoph Janser, Florian Vock, Henry Hohmann, Lovis Cassaris, Max Krieg, Patrick Rohr, Peter Gabriel Maria Christen, Selma, Thomas Fuchs, Udo Rauchfleisch, Wuddri Rim

Thomas Fuchs darüber, wie ein glückliches Leben mit Kindern gelingt, warum dabei Anerkennung so wichtig ist und wie gute Stimmung auch zu Weihnachten gelingen kann

Show Notes EuRuKo 2018 Vienna (https://euruko2018.org/) Thomas Fuchs (http://mir.aculo.us/) Amy Hoy (https://twitter.com/amyhoy) Beginning Ruby (https://www.amazon.com/o/ASIN/1484212797/parpaspod-20) POODR (https://www.amazon.com/o/ASIN/0134456475/parpaspod-20) 99 Bottles of OOP (https://www.sandimetz.com/99bottles/) Elixir Forum (https://elixirforum.com/) ElixirConf EU 2018 Highlights (https://www.youtube.com/watch?v=ncv-D8GbNBg) Ruby Habits (https://rubyhabits.github.io/) vienna.rb (https://www.meetup.com/vienna-rb/) This Bot Will Pump You Up (https://www.youtube.com/watch?v=_II771f7p4g) What Are Flame Graphs and How to Read Them (https://www.youtube.com/watch?v=6uKZXIwd6M0) Recommendations Book Yourself Solid (https://www.amazon.com/o/ASIN/1119431220/parpaspod-20) Get Clients Now! (https://www.amazon.com/o/ASIN/081443245X/parpaspod-20) Cooking by Hand (https://www.amazon.com/o/ASIN/0609608932/parpaspod-20) Metaprogramming Ruby 2 (https://www.amazon.com/o/ASIN/1941222129/parpaspod-20) Aaron Cruz Twitter (https://twitter.com/mraaroncruz) Personal Page (https://aaroncruz.com/) Parallel Passion Patreon (https://www.patreon.com/parpaspod) Twitter (https://www.twitter.com/parpaspod) Instagram (https://www.instagram.com/parpaspod) Facebook (https://www.facebook.com/parpaspod) Credits Tina Tavčar (https://twitter.com/tinatavcar) for the logo Jan Jenko (https://twitter.com/JanJenko) for the music

"Ein echter Junge zu sein, ist heute eine Diagnose.” sagt Dr. Thomas Fuchs im Interview und bezieht sich darauf, dass Kinder zu häufig in eine Schublade gesteckt werden und gewissen Verhaltensmustern folgen sollen. Dabei ist es so wichtig, die Einzigartigkeit jedes Kindes zu respektieren und auch zu fördern. Im Interview verrät er unter anderem, was Einzigartigkeit bedeutet, warum die Einzigartigkeit deines Kindes so wichtig ist, wie man diese erkennt und fördert. Daneben erzählt er, warum regelmäßige Rituale entscheidend für ein entspannteres Familienleben sind. **Heute im Interview:** Dr. Thomas Fuchs (verheiratet, 3 Töchter) ist Diplom Psychologe und seit vielen Jahren als Kinder- und Jugendpsychologe sowie als klinischer Verhaltenstherapeut tätig. Promoviert hat er zum Thema Aufmerksamkeitsdefizit- und Hyperaktivitätsstörungen. Er arbeitet als Supervisor und systemischer Coach für Gruppen und Unternehmen und ist ein gefragter Vortragsredner, insbesondere über neue Erziehungsansätze und die Vereinbarkeit von Beruf, Familie und Partnerschaft. Zusammen mit Persönlichkeitscoach Jens Corssen hat er das Buch Familienglück geschrieben. **Die Themen des Interviews** - Wie sieht der Alltag in der Praxis aus von Dr. Thomas Fuchs aus? (ab 1:20) - Was sind die typischen Themenfelder und Fragen, mit denen Familien zu Dr. Fuchs kommen? (ab 2:09) - Wann sollte eine Familie sich professionelle Hilfe von einem Psychotherapeuten suchen? (ab 3:30) - Gibt es auch Eltern die zu Ihnen kommen, um im Familienalltag etwas zu optimieren? (ab 5:10) - Was bedeutet Einzigartigkeit des Kindes? (ab 5:55) - Wie erkenne ich die Einzigartigkeit des Kindes? (ab 10:20) - Wie gehe ich als Mutter/Vater damit um, dass das Umfeld die Einzigartigkeit meines Kindes nicht akzeptiert? (ab 12:00) - Wie kann ich das Kind im Alltag in seiner Einzigartigkeit unterstützen? (ab 15:14) - Sollte ich meinem Kind erlauben, weniger Hausaufgaben zu machen, wenn es lieber draußen spielt? (ab 20:33) - Welche regelmäßigen Rituale gibt es für ein glückliches Familienleben? (ab 21:40) - Wie kann ein Familientreff aussehen? (ab 27:42) - Wie bekomme ich Kinder dazu, sich zu öffnen? (ab 30:27) - Welchen Ratschlag haben Sie an gestresste Mütter/Väter? (ab 32:41) - Welche 3 Tipps würden Sie neuen Eltern mit auf den Weg geben? (ab 36:41) Feedback an: feedback@kumino.de

Amy Hoy is known for her unfiltered, straight-shooting opinions on building product businesses. Her and her husband  Thomas Fuchs have built  Freckle, an awesome time-tracking web app - and have become well known in the bootstrapping, design, and Ruby on Rails communities. Amy is also a passionate teacher: her and Alex Hillman run the excellent  30x500 bootcamp whose students include the likes of Brennan Dunn,  Chris Hartjes, and  Jaana Kulmala. Our topic was: finding an audience, discovering needs, and building products people want. Notable quotes "The core problem with so many businesses is that they’re based on what the business owner wants." "They’re fantasizing about being the hero: “I’m going to ride in on my white ‘software’ horse, and save these poor people." "As much as you can, you want to sell to people who will use your product. People who buy your product and don’t use it will never buy from you again." "Target people already in motion." "Selling to wannabes has the least amount of upside; people who already have a business are more likely to spend money.” "I would rather have no money, than know that the vast majority of people that gave me the money aren't achieving what they wanted to. If that's true, I don't want to be in that business." "Being in business forces you to become a better human being." Show notes Freckle Time Tracking 30x500 Amy's blog post on why Freckle became successful The legend of 30x500A note from Justin: A big thanks to Amy Hoy for being Amy: no bullshit, nothing held back. Just real, hard advice for product people. Cheers, Justin Jackson @mijustinPS: I'm writing a new book right now called Marketing for Developers. Click here to sign-up for updates (and get a sample PDF).

Adam talks with Amy Hoy and Thomas Fuchs, Founders of Slash7 about product development, profiting from Open Source, the key to happiness, living a Unicorn-Free lifestyle and how Amy and Thomas met and ultimately fell in love.

Adam talks with Amy Hoy and Thomas Fuchs, Founders of Slash7 about product development, profiting from Open Source, the key to happiness, living a Unicorn-Free lifestyle and how Amy and Thomas met and ultimately fell in love.

Wynn caught up with Thomas Fuchs to talk about script.aculo.us, Scripty2, Zepto.js and the future of Prototype.

Wynn caught up with Thomas Fuchs to talk about script.aculo.us, Scripty2, Zepto.js and the future of Prototype.